[{"article": "WEDNESDAY, Aug. 17, 2011 (HealthDay News) -- People who have narrowed carotid arteries in the neck and show no symptoms may be at risk for stroke and not know it, but a simple ultrasound test can identify the problem, a new study suggests.\nThe report was published in the Aug. 17 online edition of Neurology.\nEach participant had an ultrasound to see if there were signs that a stroke might occur.\nThe problem is identifying the patients at the highest risk for stroke, he said.\nBut those at highest risk may need a surgical procedure called an endarterectomy, which clears the carotid arteries of plaque.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included no discussion of costs.\u00a0 How much would these methods cost?", "answer": 0}, {"article": "But after controlling for those risk factors, \"the difference [in brain aging] is still there so we conclude that omega-3 fatty acids likely explain them,\" Tan said.\nAnother possibility is that the slight mental decline that the people in the older brain group were experiencing caused them to eat less healthy omega-3-rich foods, instead of vice versa.\nThe study, published in the Feb. 28 issue of the journal Neurology, did not prove that omega-3 fatty acids prevent mental decline, merely that there may be an association between consumption of fatty acids and brain health.\nIn the meantime, fish is \"a good prescription for other things and we have a hint it might be helpful for the brain,\" Scarmeas said.\nBut in the current work, researchers could estimate the amount of omega-3s that participants had consumed in the past several months by looking at how much had built up in their red blood cells.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of fish is not in question, although a word about the cost of fish oil supplements would not have been inappropriate.", "answer": 2}, {"article": "He reviewed the study but was not involved in it.\nIn their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nAs for false positives, 1 percent of the women without a history of breast cancer were referred for biopsy but ended up being cancer-free, compared with 1.7 percent of those with a breast cancer history.\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\nFor those who have dense breasts and are younger than 50, for example, \"we can alternate mammograms with breast MRIs,\" with one of the tests every six months, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not include information about the psychological and financial costs\u00a0of biopsies for\u00a0women with a false positive diagnosis of breast cancer.\u00a0 Among women with a personal history of breast cancer, 1.7 %\u00a0were referred for\u00a0biopsies that determined there was no second\u00a0breast cancer while 1% of the women without breast cancer had false positive determinations.\nThe article does point out that 18% of women with a personal history of breast cancer were called back for additional imaging or biopsies compared with 8.3% of those without breast cancer but there is no discussion of the psychological or financial costs connected with the additional imaging.", "answer": 0}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Unfortunately, like the earlier Times\u00a0story, the WSJ story doesn\u2019t mention costs, either those associated with taking prescription or over-the-counter drugs to treat insomnia or those associated with cognitive behavioral therapy. The closest the story comes to mentioning cost is when it notes that one problem with the use of prescription sleep aids is that insurance may not cover long-term use; this would have been an obvious point at which to note how expensive these drugs can be. The story suggests that cognitive behavioral therapy can be effective after as few as two sessions, but it doesn\u2019t say how many sessions the average patient requires, how expensive those sessions are likely to be nor how likely it is that insurance would cover this type of therapy.", "answer": 0}, {"article": "But the mind is a powerful thing.\nThe second study, published in 2013, had a similar set up \u2014 37 people complaining of gastrointestinal problems, randomized into high-gluten, low-gluten and no-gluten groups.\nIf you are cutting out gluten for any other reason, all that will happen is you\u2019ll feel the same, but without the pleasure of bread that tastes like bread.\nTo really get a sense of whether gluten sensitivity is a thing, researchers need to conduct a double-blind randomized controlled trial in which one group eats gluten, another does not, and no one knows which group they are in.\nIf you think avoiding gluten will make you feel better, there is a reasonable chance that it will \u2014 even if gluten is irrelevant.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story does mention that there are now a broad range of gluten-free foods on the market, it does not discuss the increased costs associated with those products.\u00a0One additional sentence would have made a really good story a little bit better.", "answer": 0}, {"article": "In the meantime, she cautions Alzheimer\u2019s patients not to rush out and try to take insulin.\nThe problem was to find a way to get more insulin to the brain but not to the body.\nThe lower dose seemed more effective than the higher one.\nThose who received placebos got worse.\nAnd conditions in which the body makes too little insulin or is resistant to its effects \u2014 diabetes, prediabetes, even untreated high-blood pressure \u2014 are associated with an increased risk of Alzheimer\u2019s.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention the cost of insulin. This information is readily available and would have provided valuable context. There will also be the cost of the specialized inhaler.", "answer": 0}, {"article": "Tens of thousands?\nLongo, the NEJM editorialist, says he'd be more convinced if the placebo patients had received infusions of white blood cells that had been exposed just to the general immune-stimulating part of the Provenge treatment, without the prostate antigen part.\nThe way the study was done, he says, \"does not allow one to conclude\" that Provenge is working because it mobilizes the immune system specifically against prostate cancer.\nThe primary mystery is how Provenge extends life, since it doesn't shrink prostate tumors, as far as anyone can tell.\n\"Prolongation of survival without a measurable antitumor effect is surprising,\" writes Dr. Dan Longo of the National Institute on Aging in a NEJM editorial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story itself only says \"it\u2019s pretty pricey.\"\u00a0 But those words provide a hyperlink to another NPR\u00a0story that discloses the drug cost as $93,000.\u00a0 It would have taken the same amount of space to just state the cost in the current story.\u00a0 Why make people click away to get the cost in another story?\u00a0 Is the need to improve click rates driving this? Regardless, we\u2019ll give the story the benefit of the doubt on this. \u00a0", "answer": 1}, {"article": "The men in the trial received the ADT drugs for two years.\n\u201cIt really builds on some prior data and combines prior findings to ask and answer a new question that is quite relevant for men affected by prostate cancer.\u201d\n\nSome patients benefitted from adding the drugs more than others.\nThe findings should trickle down to clinical settings \u201cpretty quickly,\u201d said Dr. William Shipley, chair of the genitourinary oncology unit at Massachusetts General Hospital and one of the researchers behind the study, which was published Wednesday in the New England Journal of Medicine.\nThe specific ADT drug used in the study, bicalutamide, has since been largely replaced by another kind of drug that decreases the amount of testosterone the body produces.\nThe drug, a type of androgen-depleting therapy, is a frontline treatment for men who opt not to have surgery for the cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No treatment costs are shown, for either radiation or hormone blocking. According to a 2015 study in the journal Future\u00a0Oncology, the average cost per hospital stay was $12,268, while outpatient clinic visits tallied about $4,364 per visit (surgery and radiation). However, given multiple visits, the typical prostate cancer patient can expect a lifetime cost of about $110,000.\nBut adding in hormone blockers, also called androgen deprivation therapy, according to a 2007 study in The Journal of Urology, can double the cost of a man\u2019s care.\u00a0Newer drugs that are being used now might cost more, too.", "answer": 0}, {"article": "ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL COVERAGE.\nAlthough the difference between treatment groups is modest, a statistically significant improvement shows that, overall, people with advanced squamous lung cancer can benefit when immunotherapy is added to standard treatment, according to the authors.\nOutcomes for only two of the groups, however, are being reported in this presentation:\n\nOutcome data for the third treatment group, which received atezolizumab with a slightly different chemotherapy regimen (carboplatin and paclitaxel), are not yet available.\nAlthough the rate of severe side effects was higher with the combined modality treatment than with chemotherapy alone (68% vs. 57%), it had a manageable safety profile, consistent with known safety risks of the individual therapies.\nKey Findings \n\n In this study, 29% of all patients, regardless of PD-L1 expression, had a reduced risk of disease worsening or death, compared with those who received chemotherapy alone.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention cost, which is an important point in this case, because each treatment with atezolizumab (Tecentriq) can cost more than $8000. These patients were treated every three weeks, which would produce bills upwards of $12,000 per month.", "answer": 0}, {"article": "The findings are mixed on substance abuse.\nA recent review by Canadian researchers, focusing specifically on mindfulness meditation, concluded that it did \u201cnot have a reliable effect on depression and anxiety.\u201d\n\nTherapists who incorporate mindfulness practices do not agree when the meditation is most useful, either.\nAfter practicing mindfulness meditation, she continued to feel anxious at times but told Ms. Logan, \u201cI can stop and observe my feelings and thoughts and have compassion for myself.\u201d\n\nSteven Hayes, a psychologist at the University of Nevada at Reno, has developed a talk therapy called Acceptance Commitment Therapy, or ACT, based on a similar, Buddha-like effort to move beyond language to change fundamental psychological processes.\n\u201cWith the really hard stuff, you need something else, something that allows people to tolerate these very strong emotions.\u201d\n\nIn the 1990s, Dr. Linehan published a series of studies finding that a therapy that incorporated Zen Buddhist mindfulness, \u201cradical acceptance,\u201d practiced by therapist and patient significantly cut the risk of hospitalization and suicide attempts in the high-risk patients.\n\u201cIt\u2019s a shift from having our mental health defined by the content of our thoughts,\u201d Dr. Hayes said, \u201cto having it defined by our relationship to that content \u2014 and changing that relationship by sitting with, noticing and becoming disentangled from our definition of ourselves.\u201d\n\nFor all these hopeful signs, the science behind mindfulness is in its infancy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost of treatment is not mentioned, but the story includes an excellent sidebar noting additional (free or low-cost) forms of mindfullness therapies and their demonstrated benefit\u00a0 to date. The story also adequately describes the practice and provides resources for personal practice. It would still have been helpful to hear a range of costs for therapy (and typical number of sessions for the patient to master the technique) for a common problem, such as anxiety disorder. ", "answer": 1}, {"article": "\u201cThe journal knew it.\u201d\n\n\u201cThe question for the journal, given that the authors worked for the company, is, \u2018Do we publish something like that?\u2019\u201d\n\nJohnston said there was an ongoing debate about whether or not scientists who review studies should know about potential industry interests.\n\u201cScientifically there are no data there,\u201d he said about one of the company\u2019s experiments.\n\u201cThe reader can\u2019t do anything,\u201d said Johnston.\n\u201cIt wasn\u2019t being hidden that they worked for the company,\u201d Johnston told Reuters Health.\nThe same goes for the tan.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs not discussed and it could have been frosting on this story. ", "answer": 0}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We aren\u2019t provided with any numbers, but the story does speak to the issue of cost. \u201cBut many centers, citing mixed findings on the devices\u2019 benefits, have either abandoned or have been reluctant to offer the treatment, which is costly and complex to provide. Insurers, too, have been skeptical of the procedure\u2019s value, and many refuse to reimburse for it.\u201d \nCost would be difficult to pin down precisely for this procedure, since it varies by device type and by hospital, but it would have been helpful to provide a ballpark figure.", "answer": 1}, {"article": "\"Right then, I thought, \u2018Oh, why did I do this?\nBy the time he was 14, he had lost about 70 percent of his hearing and was wearing hearing aids in both ears.\nBerryhill said the cost of the implant and surgery is in excess of $60,000, but it is covered by most insurance companies as well as Medicare and Medicaid.\n'\u201d\n\nBecause the sounds generated by cochlear implants are different from sounds received naturally by the ear, it takes time to learn to interpret what they mean.\nNow, he hears the melodies and harmonies just as well as his bandmates.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story cites a physician who says the cost of the device and surgery is about $60,000, and that it is covered by most insurance companies, Medicare, and Medicaid.", "answer": 1}, {"article": "\"In addition, it is unknown whether bevacizumab [Avastin] increases survival when added to cisplatin-based chemotherapy in patients with advanced non-squamous non-small-cell lung cancer,\" Pirker said.\nThey find that there are real deleterious side effects but that they are manageable, and conclude the drug is worth using under the proper circumstances,\" he said.\nIt's possible the FDA will withdraw approval of Avastin as a breast cancer treatment.\nThese patients were given the drug every three weeks along with standard chemotherapy, for up to six cycles.\nThe patients were treated at centers in 40 countries around the world.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion about the cost estimates for adding Avastin to treatment, nor any mention of the route of administration.", "answer": 0}, {"article": "Agatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\n(CNN) -- Most heart attacks strike with no warning, but doctors now have a clearer picture than ever before of who is most likely to have one, says Dr. Arthur Agatston, a Miami cardiologist and author of the best-selling South Beach diet books.\n\"There is a large group in the middle called intermediate risk, which may be as much as 50% of the population,\" said Dr. Erin Michos, a cardiologist at the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins University\n\nA good candidate for a coronary calcium scan, she says, would be a 50-year-old man with slightly elevated cholesterol and a father who had a heart attack.\n\"There are a lot of little old ladies in their 80s with very high cholesterol who have squeaky clean vessels.\n\"Do you put this 50-year-old who has this family history on a statin medication with potential expense (and) side effects for the next four decades of his life, or do you further refine how far at risk he is?\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does discuss costs. However, it low-balls what people may be actually charged for the scans, which may include facility fees, reading charges and other costs. For example, one insurance company cost calculator (https://www.alegent.com/body.cfm?id=4735) estimates the cost of heart CT scan for calcium to be more than $600 and a carotid ultrasound to be about $700 for people paying for their own scans, so instead of the \u201cless than $100 for both\u201d figure reported in this story, a person getting both scans might be hit with a bill for well over $1000. Also, the statement that these scans are \u201coften covered by insurance\u201d is misleading, since insurers are likely to cover the scans only for patients considered to have an elevated risk, not for everyone. For example, Aetna, one of the largest insurers in the United States, considers coronary calcium scoring investigational, not medically necessary. See http://www.aetna.com/cpb/medical/data/200_299/0228.html\n \n\u00a0", "answer": 0}, {"article": "\"It's almost like giving your brain a physical.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\n\"The brain, in its development, while it is actively developing, seems to be less able to take these forces and to really rebound from these forces,\" Dr. Gioia observed.\nNoting the difficulty of managing something that can't be measured, Michael Collins, a University of Pittsburgh Medical Center, Ph.D., developed an exam, known as an 'Impact' test, to gauge attention span and memory, and help determine whether a person has a concussion.\nBut, Regan adds, diagnosing them can be daunting: While there are some physical symptoms such as headaches, nausea, dizziness and blurred vision, concussions don't cause bleeding or swelling in the brain and don't show up on X-rays.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\nThere is no mention of the costs associated with using the Impact system or other neurocognitive tests, in either dollars or time (e.g. training, testing, and interpretation). The story does not attempt to compare costs of this system with other systems that might help a physician determine when an athlete should return to play.\n", "answer": 0}, {"article": "Could root canal procedures go by the wayside in the not-too-distant future?\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\nWhen dental pulp disease and injury happen, a root canal is typically performed to remove the infected tissues, explained Dr. Adam Celiz, Marie Curie Research Fellow at the University of Nottingham.\n\"We're trying to provide an alternative material, an alternative therapy,\" he said, because the current method involves the dentist removing all of the infected pulp tissue, \"scraping it out, and it can be very painful.\"\nIt's like this material goes over and just taps it on the shoulder and says, 'Wake up, wake up,' and then it starts to repair itself.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address the potential cost of this procedure and how it might compare to a root canal, but this is important to consider since root canals are very expensive, and presumably a procedure involving stem cell regeneration would be, too. According to one consumer information website, a root canal costs between $585 to $1,400 depending on the location of the dentist\u2019s office and the type of tooth. Those estimates do not include restorative procedures such as crowns, posts and cores, and fillings, which can cost hundreds or thousands of dollars more.", "answer": 0}, {"article": "Marion Nestle, a nutrition professor at New York University, says longer studies conducted among people in their own environments, not with such controlled meals, have shown \"little difference in weight loss and maintenance between one kind of diet and another.\"\nThe diets had the same number of calories, but the fat, protein and carbohydrate content varied.\nThe reason for the low-carb advantage is unclear, he says.\nWhen the body thinks it's starving, it turns down metabolism to conserve energy,\" he says.\nThe dieters were admitted to the hospital four times for medical and metabolic testing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of these diets is not really in question. We\u2019ll call it not applicable.", "answer": 2}, {"article": "Funding for HAB comes from Hass avocado producers and importers in the United States.\n(See conclusion of study)\n\n\"Interestingly, our results indicate that even healthy subjects with a relatively normal baseline TC (100 to 240 mg/dL), LDL-C (75 to 150 mg/dL), and TG (50 to 175 mg/dL) had significant reductions,\" says Sachin Shah, PharmD, corresponding author and expert in cardiovascular health.\nThe research, \"Impact of avocado-enriched diets on plasma lipoproteins: A meta-analysis,\" conducted at the University of the Pacific and independently funded , looked at 10 unique avocado studies with 229 participants, assessing the impact of avocados on cholesterol levels.\nOn the heels of this advice, a new meta-analysis (considered the best evidence and an unbiased overview of the body of knowledge on a specific topic), published in the Journal of Clinical Lipidology, adds to the growing body of research that supports the use of avocados in lieu of solid fats (and foods that have higher saturated fat content) to significantly change lipid profiles.\n\"Fresh avocado, as part of a balanced diet, and as a cholesterol-free substitute for solid fats, can help be part of the solution for maintaining normal cholesterol levels,\" says Nikki Ford, PhD, Director of Nutrition, Hass Avocado Board.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Avocados are expensive and that should be acknowledged when advising consumers to add 1 or 1.5 daily to their diets. According to the Hass Avocado Board\u2019s own website, the average retail price of a conventionally grown avocado is $.89, while an organic one is $1.52.\u00a0 A family of four could potentially spend $25 to $42 a week on avocados alone were they to adopt the release\u2019s recommendation.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs of hormone therapy.", "answer": 0}, {"article": "For more information about ColonaryConcepts, LLC, please visit http://www.\nThe study tested six formulations of ECP, using different doses of the active ingredients integrated within different meal kit menus, randomized against two U.S. Food and Drug Administration-approved active comparators.\nThe proportion of patients reporting being satisfied or extremely satisfied with the experience of using the lead ECP formulation was nearly double that for those using the standard preps, 64.3% versus 33.3%.\nFor the comparator products, 85.7% (12 of 14) had a rating of excellent or good.\nThe investigational prep is designed to be good-tasting, with no fasting and lower fluid requirements than standard preps.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the prep is still moving through clinical trial stages, the anticipated cost of this new formulation will be front-of-mind among folks reading stories about it.\u00a0 The earlier this kind of information is offered the better.", "answer": 0}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given that the premise of the story is explaining there is no benefit to taking these supplements, we\u2019ll rate this N/A. That said, it would have been interesting to explore the cost-savings for people if they decide to stop buying calcium and vitamin D.", "answer": 2}, {"article": "But you can't make any conclusions about definite health benefits\" based on the study findings, said lead author Suzanna M. Zick, a naturopathic physician and research associate professor at University of Michigan Medical Center, Ann Arbor.\nThe amount of ginger in the pills is equivalent to 20 grams of raw ginger root, the authors said.\nThe researchers found that the level of inflammation in the subjects who took the ginger pills fell by an average of 28 percent, while staying about the same in those who took the placebo.\nIt's already clear that people with inflammatory conditions such as inflammatory bowel disease are at higher risk of colon cancer, he noted.\n\"If you want to add ginger to part of a healthy diet, that's great.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that a month\u2019s supply of ginger supplements typically runs about $10 \u2013 $30.", "answer": 1}, {"article": "PITTSBURGH, June 2, 2016 - Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute (UPCI) professor revealed.\nNearly 42 percent of the women who received surgery lived to five years after diagnosis, compared with less than 25 percent of the women who did not receive surgery.\nAt about 40 months after diagnosis, the women who received the surgery plus standard therapy lived an average of nine months longer than their counterparts who received standard therapy alone.\nDr. Soran began the trial in 2007, ultimately recruiting a total of 274 women newly diagnosed with stage IV breast cancer from 25 institutions.\n\"Our thinking is similar to how you might approach a battle against two enemies,\" said Dr. Soran.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs in the release. This would be an easy addition, given how common these types of surgeries are.", "answer": 0}, {"article": "Despite the fact that a link between taking folic acid and reducing autism risk isn't fully proven, Halladay says there's no harm in taking the supplement, and women should be taking it anyway to prevent birth defects.\nThe same dose appears to provide some benefit in preventing autism, according to the research.\n\"Caring for individuals with autism and their families would be a whole lot easier if we had simple answers about cause and risk,\" he says.\n\"This is another piece of evidence that supports the beneficial uses of folic acid during pregnancy,\" said Halladay, who was not connected with the study.\nResearchers in Norway looked at data from 85,000 pregnancies, and found that women who took the supplement four weeks before pregnancy, and through the eighth week of pregnancy, were 39% less likely to have children with autism.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of folic acid supplements is not in question.", "answer": 2}, {"article": "4364.0.55.001, March.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\nThe results show that the dairy-supplemented MedDiet (MedDairy) significantly improved blood pressure, heart rate, cholesterol, mood and cognitive function.\n\u201cThe new MedDairy diet allows for three to four servings with dairy, which means Australians can more sustainably meet their recommended daily nutrient intakes while also maintaining the significant health benefits offered through the MedDiet.\nAnd if you\u2019re one of the thousands of people seeking to improve your cardiovascular and cognitive health \u2013 look no further than the MedDairy diet.\u201d\n\u2022 Cardiovascular disease (CVD) is a major cause of death in Australia, with 43,477 deaths attributed to CVD in Australia in 2017.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t discuss the costs of adhering to a dairy-supplemented Mediterranean diet. However, many people know the costs for typical Mediterranean diet food items like nuts, fruits, and fish and dairy products like milk and cheese.", "answer": 2}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost of treatment not mentioned.", "answer": 0}, {"article": "D'Amico, chief of the Department of Plastic Surgery at Englewood Hospital and Medical Center in Englewood, N.J.\nThe cost of contouring can run into the tens of thousands of dollars, depending on how many procedures are needed.\nThere are no guidelines requiring bariatric surgeons to warn their patients, although recently professional societies of plastic surgeons and bariatric surgeons have begun holding seminars to discuss the idea.\nMost insurers pay for bariatric surgery, but they often consider contouring to be cosmetic, rather than medically necessary, and thus not covered under their policies.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of contouring are presented as tens of thousands of dollars; in addition, mention is made that they are not necessarily covered by insurers.", "answer": 1}, {"article": "WASHINGTON (Reuters) - Statin drugs may lower the risk of colon cancer by as much as 12 percent, U.S. researchers reported on Monday.\nSamadder\u2019s team did what is known as a meta-analysis, combining the findings of 22 scientific studies with more than 2.5 million volunteers.\nIn May, British researchers reported that patients taking them have a higher risks of liver dysfunction, kidney failure, muscle weakness and cataracts.\nOverall, patients who took statins had a 12 percent lower risk of being diagnosed with colon cancer than people who did not take the drugs, they found.\nMany researchers have found that statin drugs, which include Pfizer Inc\u2019s Lipitor and AstraZeneca Plc\u2019s Crestor, have effects far beyond lowering cholesterol and reducing the risk of heart disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Although statin medications have been on the market for a long time and information about the costs of both name brand and generic versions of these drugs is readily available, the story included no information about costs. ", "answer": 0}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s too early to discuss\u00a0how much one of these experimental drugs might cost. But the article could have reported something about the estimated costs of currently caring for these\u00a0patients. It\u2019s also worth noting that if a drug is ever approved, it will cost Medicare a bundle.", "answer": 2}, {"article": "Nevertheless, accumulating evidence has her urging patients to get their calcium from their diet, rather than reflexively telling them to take 1,200 milligrams of calcium a day.\nA recent meta-analysis done by the same group of researchers found a 27 to 31 percent increased risk of heart attacks in women taking calcium without vitamin D.\n\nMany older women take calcium supplements with or without vitamin D to keep their bones strong, especially since that has long been standard medical advice.\n\"The cautious way forward seems to be to encourage people to obtain their calcium from the diet, rather than from supplements, since food calcium has not been shown to carry this increased risk of heart disease,\" Reid added.\n\"There is a lack of consensus at the present time as to what recommendations should be regarding the use of calcium supplements,\" said study senior author Dr. Ian Reid, who fully expected that the new results will have a \"significant impact on recommendations.\"\n\"If women have good reason to take calcium because their bones are thin, then they should not be afraid of taking the calcium,\" said Houck, who is also a cardiologist with Scott & White in Temple, Texas.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs. Given that calcium supplementation can last for decades, we think costs would have been important information and easy to access. Although calcium supplements are inexpensive for the individual, the amount of money in aggregate that is spent on supplements would be an important piece of context.\n", "answer": 0}, {"article": "It can be very unpleasant.\n\u201cScratching leads to swelling, cracking, weeping clear fluid, and finally, coarsening and thickening of the skin.\u201d\n\nThere are many treatments out there now, from simple skin lotions to steroid creams and immune suppressant drugs like tacrolimus.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\n\u201cThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching,\u201d the FDA notes.\n\u201cOf the adults with uncontrolled moderate to severe atopic dermatitis in the United States, it is estimated that 300,000 are most in need of new treatment options,\u201d Regeneron said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a barely passing satisfactory rating\u2013the story did disclose the cost of $37,000, but overlooked some important details when it then tried to explain that manufacturers think the actual cost to patients will be lower.\nThe full picture is more complicated. Drug company patient-assistance programs \u2014 which help patients cover co-payments and other out-of-pocket costs \u2014 are abhorred by economists because they shield patients from treatment costs and undermine the ability of insurers to steer patients to less expensive options.\nIn addition, an accompanying video states \u201ca billion and a half dollars\u201d was spent developing the drug but doesn\u2019t point out that the purported development cost is small compared with the potential profits. If all 300,000 people the manufacturers of this drug say are \u201cmost in need of treatment options\u201d receive this drug, the total cost could be as high as $11 billion a year, funds that must be diverted from other healthcare priorities or come from higher premiums or taxes. That broader analysis was missing in this story.\nAn independent draft analysis showed dupilumab did improve health outcomes compared to usual care but with additional costs, and that the drug did fall below commonly cited standards for cost-effectiveness. Still, the study relied on some uncertain variables and found the drug was most cost effective for patients with severe conditions.", "answer": 1}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no cost data. Gilenya costs $8,210 for a 30-day supply, according to the web site drugs.com.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - The inexpensive tests that look for hidden blood in a person\u2019s stool are effective for colon cancer screening, a study out Tuesday confirms.\nAdvances in the stool tests in recent years have made them more effective.\nImmunochemical FOBT is now largely replacing the older test.\nMore than 50,000 Americans died of the disease in 2010.\nThat\u2019s particularly important in Asia, where those cancers are common.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of FOBT and of colonoscopy were included.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\n\u201cIf these findings are confirmed in larger studies, HDIT/HCT may become a potential therapeutic option for patients with active relapsing-remitting MS, particularly those who do not respond to existing therapies,\u201d said Daniel Rotrosen, M.D., director of NIAID\u2019s Division of Allergy, Immunology and Transplantation.\n\u201cAlthough further evaluation of the benefits and risks of HDIT/HCT is needed, these five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS,\u201d said Richard Nash, M.D., of Colorado Blood Cancer Institute and Presbyterian-St. Luke\u2019s Hospital.\n\u201cThese encouraging results support the development of a large, randomized trial to directly compare HDIT/HCT to standard of care for this often-debilitating disease.\u201d\n\nMS symptoms vary widely and may include motor and speech difficulties, weakness, fatigue and chronic pain.\nThe most common form of MS is relapsing-remitting MS, which is characterized by periods of mild or no symptoms interspersed with symptom flare-ups or relapses.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of the cost of stem cell transplants. We could find no reliable cost estimate online, but several sources including the American Cancer Society put the price in the hundreds of thousands of dollars. Transplants that use a patient\u2019s own stem cells, known as autologous transplants, are cheaper than those that use donor cells.", "answer": 0}, {"article": "The devices had been developed at EV3 Inc., a Plymouth med-tech company that Covidien acquired in 2010.\nHe said he has no financial stake in the company.\nBlockages can result in severe pain, limited mobility and nonhealing leg ulcers.\nIt occurs when arteries in the legs become narrowed or blocked by plaque.\n\"This particular product plays very strongly into where we see the market going,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs of atherectomy nor of the tool in question.", "answer": 0}, {"article": "Current testing for tuberculosis (TB) involves looking at sputum (respiratory mucus) under a microscope.\nThe test costs about $63 in Europe, but the company has agreed to provide it for less than half that in poor countries, said John Bishop, Cepheid's chief executive officer, as quoted in a story by the Associated Press.\nFor the study, a research team led by Dr. Catharina C. Boehme, of the Foundation for Innovative New Diagnostics in Geneva, Switzerland, used the Xpert MTB/RIF test on 1,730 patients suspected of having drug-sensitive or multidrug-resistant pulmonary tuberculosis.\n\"The test also indicates rapidly whether difficult-to-treat, drug-resistant forms are present,\" he said.\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does more than pay lip service to cost, flagging it as the key to making this test available in the developing world.\u00a0It notes the price tag of\u00a0the diagnostic machine itself and says that the $63 cost\u00a0per test may be discounted by more than half in developing world countries.\u00a0It fails\u00a0however to compare the\u00a0cost of the new test with\u00a0the existing TB test. Even more important, it fails to explain that a $20 or $30\u00a0expense,\u00a0which might sound modest to U.S. readers, would actually represent a huge cost burden in many developing world countries, where\u00a0annual per capita health care expenditures are sometimes less than $30.\u00a0A close call, but since the story made a good-faith effort to address this issue, we\u2019ll award a satisfactory with deficiencies noted. \u00a0\u00a0\u00a0", "answer": 1}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of cherries is not in question (although one of our reviewers recently got a spouse-scolding for NOT checking price and coming home with $18 worth of cherries!)", "answer": 2}, {"article": "At 20 mg the difference was 10.4 percent and at 10 mg, 4.7 percent.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\nThe most common side effects included upper respiratory tract infection, urinary tract infection, dizziness, drowsiness on waking, headache and vivid dreams.\nThe improvement was 11.6 percent at 40 mg, 6.6 percent at 20 mg and 6.2 percent at the lowest dose.\nOn average, it took patients 21.6 fewer minutes to fall asleep with the 40 mg dose of MK-4305 than a placebo on night one, Merck said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No. And this really is a shame because there are a lot of sleep aids on the market. Given the doseage, there could have been a way to talk about what drug this might replace or compete with and how much that drug costs, at a minimum.", "answer": 0}, {"article": "For others, it\u2019s relationship based.\nThe issue of a woman\u2019s libido is more complicated than the dysfunction treated by the well-known little blue pill, according to women\u2019s sexual health experts.\nIf it\u2019s hormonal, (flibanserin) isn\u2019t going to help, and if you\u2019re in a lousy relationship, it\u2019s not going to help that.\u2019\u2019\n\nThe issue of decreased desire affects marriages and a woman\u2019s self esteem, Goldstein and other experts said.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\nBut specialty drug maker BioSante, which is working on a treatment for post-menopausal women, said the overall U.S. market for medicines to rekindle female desire is worth as much as $2 billion in annual sales.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No cost data was provided for flibanserin.\u00a0 But an estimate of the potential U.S. market, up to $100 million in sales, was given.\u00a0 Those sales estimates had to be based on some price assumptions.\u00a0 What where they? \u00a0 It doesn\u2019t seem that you should provide the one number without providing the other. How might the cost of flibanserin compare to the cost of drugs to treat erectile dysfunction? ", "answer": 0}, {"article": "CHICAGO (Reuters) - A study in rats and monkeys suggests an experimental Merck & Co sleep drug may help induce sleep without causing the memory loss and attention problems sometimes seen in the commonly used drugs Ambien and Lunesta, company researchers said on Wednesday.\nFor this study, the team wanted to find out what would happen if someone is awakened on this drug and has a very high level of it in their system.\nLevels of this compound rise during the day and fall at night.\nIn the study, rats given GABA blockers were less likely to recall the objects than those given DORA-22.\nThe most common side effects from Suvorexant have been headache and sleepiness.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Even though the drug maker has already applied for FDA approval to market a similar drug, there is no discussion of how much it will cost.", "answer": 0}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\n\u201cThe mechanism is partially due to these cells secreting certain miRNAs which help maintain youth, and the loss of these leads to ageing\u201d said Cai, whose study is published in Nature.\nWhen the molecules are produced in the hypothalamus, they flow into the clear fluid in the brain and spinal cord and affect how genes operate.\nI can see a day when we are implanted with stem cells or treated with stem cell RNAs that improve our health and extend our lives.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll give the story a \u201cN/A\u201d in this category since it makes clear early on that this research is in the earliest of stages, done in an animal model, and says clearly that clinical trials are a future hope. This is way too early to consider costs which, we assume, would be substantial.", "answer": 2}, {"article": "The researchers are continuing to evaluate that.\nThe dual-drug approach greatly boosted the chances of eliminating microscopic signs of early cancer by the time a woman was due to have surgery, said researcher Dr. Jose Baselga, chief of hematology/oncology at Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School.\nIn another study, published online Jan. 17 in The Lancet Oncology, researchers from Germany reported that Tykerb is less beneficial than Herceptin as a single-drug therapy.\nThe study is well done and important, said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society.\nThe two drugs are Tykerb (lapatinib) and Herceptin (trastuzumab).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost of Tykerb was estimated \u2013 about $4,000/month wholesale.\u00a0 No mention of Herceptin\u2019s cost.\u00a0 Strange to include one but not the other since this was a story about a \u201cdrug duo.\u201d\nCost is always an important consideration in this type of story.\u00a0 This is especially true when the drug costs are so high.\u00a0 The drug costs for the combination regimen approaches $100,000 a year.\u00a0 Since the combination treatment is not standard, insurance coverage will be spotty at best.", "answer": 0}, {"article": "The other trial had nearly identical results.\nTHURSDAY, Oct. 18, 2018 (HealthDay News) -- In what researchers are calling a \"breakthrough,\" two preliminary trials have found that either of two triple-drug regimens could potentially benefit 90 percent of people with cystic fibrosis.\n\"The ability of these potential drugs to treat individuals with a single F508del mutation means that more people than ever before could benefit,\" said Dr. Michael Boyle, senior vice president for therapeutics at the foundation.\nThis is the first time, Rowe said, that CFTR modulator therapy has \"pushed the needle\" for patients with one F508del mutation.\nWhat's most exciting, they said, is that the triple-drug approach could open up new options to nearly all cystic fibrosis patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story brought up the \u201creal-world issue of price\u201d if the drugs are approved. It reported that the company that makes them \u2014 Vertex Pharmaceuticals \u2014 markets the combination of two other CFTR modulators \u2014 tezacaftor and ivacaftor \u2014 for a list price of $292,000 a year.\nAdditional cost comes from the continued need for hospitalization on a regular basis, at least for some patients. Treating these patients may well cost millions over the course of a decade.", "answer": 1}, {"article": "WEDNESDAY, Nov. 28, 2012 (HealthDay News) -- Patients with rheumatoid arthritis are more likely to suffer hip dislocation after hip replacement surgery than those with osteoarthritis, a new study says.\nFor the study, the investigators analyzed the findings of 40 studies published between January 1990 and December 2011.\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\nIn addition, rheumatoid arthritis patients have a higher infection risk after total knee replacement than osteoarthritis patients, the study authors found.\nThe study team found no differences between the two groups of arthritis patients in rates of follow-up surgery, or 90-day blood clot or death risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the costs of joint replacement.", "answer": 0}, {"article": "\"Our results demonstrate that [Opdivo] is more effective in treating patients with stage III and IV melanoma, cutting the risk of relapse by a third,\" lead researcher Dr. Jeffrey Weber, professor of medicine at NYU School of Medicine, said in a university news release.\nAnd at 18 months, the rate was 66 percent for Opdivo and 53 percent for Yervoy, the findings showed.\n\"Based on this study, it appears that patients with advanced melanoma who have their disease completely removed by surgery should go on to receive additional therapy with Opdivo,\" said Dr. Gary Deutsch.\nThe international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.\nThe study found that patients taking Opdivo had fewer severe side effects than those taking Yervoy, at 14 percent versus 45 percent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed. That\u2019s a significant oversight given that treatment with Opdivo can reach well into the tens of thousands of dollars\u2013or more.", "answer": 0}, {"article": "She told FoxNews.com that the balloon \u201cmakes you feel full all the time to the point where you\u2019re not angry about having to lose things like chocolate and cake.\u201d\n\nBrown said that the balloon acted like a \u201crestart button\u201d and retrained her body to adapt to a new lifestyle of healthy eating and exercise.\nThe objective of the Orbera system is the make the patient feel partially satiated so they eat smaller, but more nutritious portions.\nIt is meant for people looking for an extra jumpstart on a diet, whether the purpose is cosmetic or for health reasons.\n\u201cThe beauty of the procedure is that it is a nonsurgical procedure,\u201d Chattoo said.\nPatients are treated in office and are kept under mild to moderate sedation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story clearly notes that the device, known as Orbera, \u201cis not covered by insurance and costs $8,000.\u201d", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of this drug, though it is labeled \u201cinexpensive\u201d. Inexpensive is relative and may not be viable for health centers w/out funding from clinical trials. However, there is explicit consideration of cost for resource-limited countries.", "answer": 1}, {"article": "Researchers say metabolic abnormalities that eventually lead to type 2 diabetes can be present years before diabetes is diagnosed.\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\nFor example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s a bit early for costs, since no clinical test has been devised. When we get there we can start asking how expensive\u00a0this type of\u00a0metabolite profiling is and the costs and cost-effectiveness of screening people, especially\u00a0the asymptomatic high-risk folks with normal blood sugar\u00a0identified in\u00a0this study.", "answer": 2}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\n\u201cThese findings will change the available treatment options for patients with PDR.\u201d\n\nDiabetic retinopathy damages blood vessels in the light-sensitive retina in the back of the eye.\nThe trial results \u201cprovide crucial evidence for a safe and effective alternative to laser therapy against PDR,\u201d said NEI Director Paul A. Sieving, M.D., Ph.D.\n\n\u201cPatients who received Lucentis showed a little bit better central vision, much less loss of their side vision, and substantially less risk for surgery than patients who received laser treatment,\u201d said Lloyd Paul Aiello, M.D., Ph.D., director of the Beetham Eye Institute at Joslin Diabetes Center and Professor of Ophthalmology at Harvard Medical School.\nBecause Lucentis is commonly injected to treat diabetic macular edema (DME)\u2014a build-up of fluid in the center of the retina\u2014the study permitted the use of Lucentis for DME in the laser group, if necessary.\nFunded by the National Eye Institute (NEI) and conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net), the trial compared Lucentis injections with a type of laser therapy called panretinal photocoagulation, which has remained the gold standard for PDR since the mid-1970s.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention cost at all. Since Lucentis can cost $2,000 per injection, that\u2019s a significant oversight. It would also be useful to tell readers how Lucentis injections compare with the cost of laser treatment.", "answer": 0}, {"article": "Previously, no treatment was available for these patients.\"\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\n\"This study represents a breakthrough in the management of hepatocellular carcinoma, since it provides evidence for clinical benefits in an area that was an unmet medical need,\" said Josep M. Llovet, MD, founder and Director of the Liver Cancer Program and Professor of Medicine and Liver Diseases at the Icahn School of Medicine at Mount Sinai.\nIn January, Bayer announced that the U.S. Food and Drug Administration (FDA) had granted priority review status for Stivarga (regorafenib) as a second-line systemic treatment for patients with hepatocellular carcinoma.\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed at all. This is particularly problematic because regorafenib (brand name Stivarga) has already been approved, and is on the market, for treating other forms of cancer. For example, an online price guide shows that 84 40-milligram tablets of regorafenib cost $15,817. This is a fair estimate of the cost of treatment, given that the initial treatment regime for patients in the clinical trial receiving regorafenib was 84 40-milligram tablets (four 40-milligram tablets per day for 21 days).", "answer": 0}, {"article": "J&J also said Cosentyx demonstrated quicker effectiveness than Tremfya during the study.\nWith $2.1 billion in sales in 2017, Cosentyx has become one of the top revenue earners for Novartis and is expected to make up for falling revenue from its blood cancer treatment, Gleevec, whose patent expired two years ago.\n(Reuters) - Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.\nAfter 48 weeks of therapy, 84.5 percent of the 1,048 participants treated with Tremfya showed 90 percent improvement in disease symptoms, as measured by the Psoriasis Area Severity Index, compared with 70 percent on Novartis\u2019s Cosentyx, J&J said.\nOn a media briefing following the release of J&J\u2019s trial results, Novartis said it expected the data to have \u201climited clinical relevance\u201d and no impact on plans to expand the Cosentyx label.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A cost comparison of the two drugs highlighted in the study \u2014 Johnson & Johnson\u2019s Tremfya and Cosentyx from Novartis AG \u2014 wasn\u2019t provided and would have been helpful.\nThe list price of a 100-mg dose of Tremfya (to be given once every two months) is about $10,000. For Cosentyx, around $4,700 (unclear if dosing is equivalent to Tremfya).\nRegardless, drug costs for severe cases of psoriasis can quickly get into the tens of thousands of dollars for some patients.", "answer": 0}, {"article": "nutritional guidelines, which I\u2019ve discussed before, says that coffee is not only O.K.\nIt\u2019s important to remember that we usually conduct those trials to see if what we are observing in epidemiologic studies holds up.\nFinally, while the coffee may be healthy, that\u2019s not necessarily true of the added sugar and fat that many people put into coffee-based beverages.\nIt\u2019s a completely reasonable addition to a healthy diet, with more potential benefits seen in research than almost any other beverage we\u2019re consuming.\nThe first reviewed 20 studies, including almost a million people, and the second included 17 studies containing more than a million people.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs, but we\u2019ll rate this Not Applicable since most coffee consumers would have some idea of how much their habit costs them.", "answer": 0}, {"article": "But he said the studies called attention to the inconsistent quality of Her2 testing in many small laboratories.\nBut scientists have now gone back and retested those preserved tumor samples and found that as many as 20 percent of them were actually Her2-negative.\n\u201cTo me, the take-home message is that we don\u2019t have a perfect test, unfortunately,\u201d Dr. Paik said.\nYet the women with those tumors also experienced a reduction in cancer recurrence from Herceptin, in some cases as great as that in the Her2-positive women.\nDr. Daniel F. Hayes, a breast cancer specialist at the University of Michigan who helped develop guidelines for Her2 testing, said it would be unwise to start giving Herceptin to Her2-negative women because the drug was expensive and raised the risk of heart failure.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story only says that Herceptin is \"expensive\" but it doesn\u2019t give cost estimates for the drug (about $20,000 per year) nor for the HER2 receptor testing.\u00a0 \n", "answer": 0}, {"article": "However, for a study that lasts this long, \u201cthose are acceptable numbers,\u201d noted Arber.\nAt a cost of several dollars per day, depending on dosage, it is much more expensive than older pain relievers such as ibuprofen.\nThis is not the first study to suggest Celebrex and similar drugs \u2014 known as COX-2 inhibitors - may reduce the risk of developing colon cancer, he said, but people need to balance that potential benefit with the higher risk of cardiovascular complications.\nThe scientists then followed the people willing to continue the research for another 2 years, noting who developed new polyps, including advanced polyps with features that suggest they\u2019re more likely to become cancerous.\nColorectal cancer is the third most common cancer in men and women, and strikes 1.2 million people each year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story manages to work costs into the discussion: \u201cAt a cost of several dollars per day, depending on dosage, [Celebrex]\u00a0is much more expensive than older pain relievers such as ibuprofen.\u201d", "answer": 1}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of the drug is not discussed. Other media coverage of this new proposed drug, fremanezumab, sets its price as high as $8,500, although it\u2019s not clear if that is for a year\u2019s treatment or a single administration.", "answer": 0}, {"article": "The efficacy and safety analyses with tramiprosate published in JPAD reveal a therapeutic effect in patients who are carriers of APOE4 after segmenting them from the larger, non-genetically-defined study population in the Phase 3 clinical program, involving more than 2,000 AD patients in North America and Europe.\nThis new insight shows how we can apply a precision medicine approach in AD and develop this drug for the right patients, namely patients with the APOE4 genotype, which carries the highest risk as well as the earliest onset and faster disease progression,\" said Martin Tolar, MD, PhD, Founder, President and CEO of Alzheon.\nThe \u03b54 allele is significantly overrepresented in the Alzheimer's disease population compared to the general population: up to 65 percent of Alzheimer's patients carry one or two copies of the \u03b54 allele compared to about 25 percent of the general population.\nPeople who inherit one copy of the \u03b54 allele, APOE4 heterozygotes, have an increased chance of developing the disease; those who inherit two copies of the allele, APOE4 homozygotes, are at even greater risk and tend to have more aggressive disease.\nAnton P. Porsteinsson, MD, Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry and Director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester in Rochester, NY, and an investigator in the North American Phase 3 clinical trial, commented: \"The genetically-defined population of APOE4 carriers has an 8-12 fold increased risk of developing AD and has more rapidly progressive disease, usually becoming symptomatic a decade earlier than non-carriers of the APOE4 genotype.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release is about clinical research on a compound that is not available yet to patients outside of an experimental setting. Even so, we wish the release had some cost context on the drug. When (or if) it debuts in the future, what might it cost?", "answer": 0}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nThe study is preliminary and doesn't prove cause and effect.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nIn a study of 232 people taking medication for psoriasis, those who also took statins had fewer of the thick, red, scaly, itchy patches that are the hallmark sign of psoriasis, compared with people who didn't take the cholesterol-lowering drugs.\nBut the findings, presented at the American Academy of Dermatology annual meeting, raise an interesting possibility worthy of further study, experts agree.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs.", "answer": 0}, {"article": "At the molecular level, genes related to the cells lining blood vessels were turned on.\nThe researchers conclude that their study, recently published in the journal Brain Stimulation, provides the first experimental evidence that whole-brain LIPUS therapy markedly improves cognitive dysfunctions without serious side effects by enhancing specific cells related to dementia's pathology.\n\"The LIPUS therapy is a non-invasive physiotherapy that could apply to high-risk elderly patients without the need for surgery or anaesthesia, and could be used repeatedly,\" says Shimokawa.\nBut there are currently no curative treatments available for vascular dementia or Alzheimer's disease, the most common causes of dementia.\nThe team, led by cardiologist Hiroaki Shimokawa, found that applying low-intensity pulsed ultrasound (LIPUS) to the whole brain of the mice improved blood vessel formation and nerve cell regeneration without having obvious side effects.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We don\u2019t see any dollar signs, but we mark this one \u201cnot applicable\u201d because the research is at such an early phase and just making the transition from animal models to clinical trials. And though it\u2019s unreasonable to speculate how much a LIPUS device or treatment may cost, if it pans out to be safe and effective, ultrasound scans can cost anywhere between about $70 and $500 per body part in 2018 dollars, according to a 2005 study.", "answer": 2}, {"article": "This test might help.\n\"Those molecules will circulate in the blood for some time, they can be measured, and you can see the contributions from essentially every tissue in the body,\" senior investigator Stephen Quake told BuzzFeed News.\n\"When you are pregnant you can see the contribution from the placenta and the fetus,\" said Quake, a professor of bioengineering and applied physics at Stanford University in Palo Alto, California.\nHowever, a new blood test \u2014 which is still experimental and not yet available outside of a research lab \u2014 can pick up on gene activity in the body that suggests a pregnancy is at risk for preterm delivery, according to a study published Thursday in the journal Science .\nThe study was funded by the March of Dimes and other nonprofit sources, although Quake and his colleagues have filed for a patent on the test.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Experimental\u00a0health\u00a0tests\u00a0don\u2019t\u00a0have public price tags. However,\u00a0this\u00a0story\u00a0gives\u00a0readers\u00a0a rare and helpful ballpark\u00a0estimate, and one that compares it to an alternative (ultrasound):\u00a0\u201cIt might be tens or hundreds of dollars, rather than thousands,\u201d a study author told BuzzFeed.", "answer": 1}, {"article": "Her research group led both studies.\nThe research involved about 200 medical interns \u2014 residents in their first post-graduate year, which is often one of the most intense periods of doctor training.\nAn earlier study of 740 interns found that suicidal thoughts increased almost four-fold during the first three months of residency, said Dr. Constance Guille of the Medical University of South Carolina in Charleston.\nInterns who got the sessions were 40 percent less likely to have suicidal thoughts during that first year compared to those who received four weekly emails with information about depressions and where to seek help.\nShe said she became very depressed but had little time to seek help.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says the study involved a free online program developed in Australia. Knowing that it is free may be incentive enough for some individual doctors or their hospitals to look into it \u2014 so this is useful information.", "answer": 1}, {"article": "These drugs work by increasing bone thickness, thereby reducing the risk of fractures, the researchers said.\nTUESDAY, Feb. 15, 2011 (HealthDay News) -- People who take drugs called bisphosphonates to prevent bone loss may also reduce their risk of developing colorectal cancer by almost 60 percent compared to those not on the drugs, a new study suggests.\n\"We also found a similar effect last year with risk of breast cancer, which has already been replicated by three other groups,\" Rennert added.\n\"The magnitude of the reduced risk is less important because this is an association study; however, it is very significant after controlling for a dozen other known risk factors,\" Rennert said.\nThe findings in this study show that bisphosphonates are associated with a reduced risk of developing colorectal cancer, but they cannot confirm a causal effect -- that is, the study doesn't prove that the use of bisphosphonates is responsible for the lower risk of colorectal cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Unlike the Reuters Health story, this story did not discuss costs. This is a shame because if the monthly cost is $10, as Reuters Health notes, that may be cheap on an individual level. As a public health policy, though, $120 a year across a huge population could add significantly to an already overspent health care system.", "answer": 0}, {"article": "The Site is down for maintenance.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Too early to discuss costs.", "answer": 2}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "As one of the experts in the story points out, \u201cthe treatment needs to be individualized.\u201d\u00a0 All therapies have costs.\u00a0 Some stab at estimating a range of time/costs could have been made. With the story discussing hospitals adopting protocols, it certainly seems a cost could be identified for a protocol.", "answer": 0}, {"article": "Such an analysis is months away.\nThere is just tremendous potential.\u201d\n\nBut Dr. Edward F. Patz Jr., professor of radiology at Duke who helped devise the study, said he was far from convinced that a thorough analysis would show that widespread CT screening would prove beneficial in preventing most lung cancer deaths.\n\u201cThe challenge now shifts from proving the efficacy of the method to developing the proper quality standards, infrastructure and guidelines to bring this needed benefit to those at high risk for the disease \u2014 now,\u201d Ms. Fenton said.\nPatients wishing to get a CT lung screen will most likely have to pay the roughly $300 charge themselves, since few insurers pay for such scans unless an illness is suspected.\nAnd they pointed out that the study offers no reassurance about the safety of smoking or the advisability of CT scans for younger smokers or nonsmokers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nMixed bag and, in the end, not specific enough to warrant a satisfactory score. \nThe story does say that a nationwide lung cancer screening program would be \u201cenormously costly,\u201d and it does mention that screening leads to additional tests and treatments. But what does \u201cenormously costly\u201d\u00a0mean? And how much could those additional tests and treatments cost? \nThe story doesn\u2019t tell readers that this type of CT scan costs about $300 (or that the trial participants each received about $900 worth of scans) and that this type of screening is generally not covered by insurance.", "answer": 0}, {"article": "Observational studies, which include all people with a condition, can never conclusively prove cause and effect, Keating acknowledged, because \"the thing we can't account for is whether people who are on a treatment are different from those who aren't.\"\nThe study she led looked at its effects on about 37,000 men treated for prostate cancer at Veterans Affairs hospitals.\n\"There has never been a trial showing an overall benefit in such cases,\" she said.\nBut lots of men get the therapy where it has not been shown to have a benefit.\"\nBut detailed evidence about the potential dangers of androgen deprivation therapy has not emerged from the more rigorous controlled trials that have been done \"because they have looked only at cardiovascular deaths, and most patients who have heart attacks do not die of those heart attacks,\" she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0This story did not discuss costs, yet it could have raised questions about the lucrative reimbursement for hormone therapy as one factor driving its use in situations where it has no proven benefit.", "answer": 0}, {"article": "Previous surgical treatment was performed on 31 of 38 knees in the study group and 37 of the 42 knees in the control group.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\nThe study group consisted of 38 patients, 10 women and 28 men who were at least 40 years of age and a control group with 42 patients (27 men and 15 women) who were 39 years of age or younger.\nThe American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\nSAN DIEGO, CA - Knee pain in active patients over 40 is often difficult to treat but according to researchers presenting their work today at the American Orthopaedic Society for Sports Medicine's (AOSSM) Annual Meeting in San Diego utilizing a special kind of allograft may be a step in the right direction.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not addressed at all. A 2007 article from Orthopedics Today\u00a0estimated the cost of an allograft at approximately $10,000. The relevant cost may have gone up or down in the intervening years, but is likely still considerable \u2014 and well worth mentioning.", "answer": 0}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The release does not mention costs. One may assume there is no cost to sleep deprivation but the deprivation in the studies was mostly monitored in inpatient facilities, which can be expensive.", "answer": 0}, {"article": "\u201cIf this is the case, dosage shouldn\u2019t matter.\nIn a new study from Duke University Medical Center, men who took statins for their hearts were 30% less likely to have their cancers come back after their prostates were removed than men who did not take the drugs.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nThose who took the highest doses saw their recurrence risk drop by half.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The lack of cost information is particularly troublesome in this case because there are so many statins on the market, and cost information would be easy to find.", "answer": 0}, {"article": "These pilot data also show that biological treatments nowadays reach far beyond medications and that new neuroscience methods may be used for targeted changes in brain regions relevant for complex mental disorders\".\nAt the end of the first 29 days of the experiment, the experimental group was given the option of continuing the treatment, whereas those in the control group were given the possibility of receiving the same rTMS treatment as the experimental group for 63 days.\nIn addition, 69% (11/16) patients) in the experimental group showed no relapse to cocaine use, whereas only 19% (3/16) patients) in the control group showed a similar positive result (the results are adjusted for patients who dropped out of the trial).\nNow a group of researchers working in Italy and the USA have shown in a preliminary clinical study that cocaine use can be reduced by treatment with rTMS (repetitive Transcranial Magnetic Stimulation).\nThis was because previous animal studies from our lab had shown that compulsive cocaine-seeking was associated with hypoactivity in the prelimbic cortex, which is a brain area that shares similar behavioural roles to the DL PFC.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the release clearly labels this work as preliminary, the overall inference of the news is that this is a potential successful treatment for cocaine addiction. But there is no mention at all of the potential cost of using this new approach.The FDA approved rTMS for major depression in December 2008. A 2013 article in Scientific American said a typical rTMS therapy session cost $300. In this study, patient volunteers underwent eight sessions which would have totaled $2,400 if paying out of pocket.\nThe costs of the drugs used to treat persons in the control group are well-known so at least those costs could be compared to that of the magnetic stimulation treatments to give readers an idea of whether the two approaches were financially comparable.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that \u201cThe filtration device costs hospitals $10,000 and each treatment requires an $800 filter \u2013 expenses that should be more than offset by lower hospital bills because of shorter stays.\u201d ", "answer": 1}, {"article": "Maia Szalavitz is a health writer at TIME.com.\nFor example, they like to line up their toys and they get very bent out of shape if there is any deviation.\u201d\n\nMORE: What Does a 400% Increase in Antidepressant Use Really Mean?\n\u201cThe clinicians could tell that people were doing better not only in terms of OCD symptoms but overall distress and ability to function.\u201d\n\nMORE: Why Are So Many Foster Care Children Taking Antipsychotics?\n\u201cRepetitive behavior is a core symptom of the illness,\u201d says lead author Dr. Eric Hollander, medical director of the Autism and Obsessive-Compulsive Spectrum Program at Montefiore Medical Center in New York, explaining that \u201cfrom a very early age, these children have rituals and routines.\nThey\u2019re more able to go outside their comfort zone and to better resist their habits and rituals.\u201d One participant in Hollander\u2019s study was previously too anxious to take the subway or eat in a restaurant, but, when taking Prozac, was able to tolerate these unpredictable environments.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s\u00a0 not that costs are high, it\u2019s just that they weren\u2019t discussed. The costs of Prozac are well known and could have been included in this story. Taking just one pill a day for 30 days would cost $214 through Drugstore.com.Prozac is generic at $10 for 3 months at one big box chain. There are also medical followup costs and possibly costs of managing adverse effects.\n\u00a0", "answer": 0}, {"article": "Federal grants helped pay for the work.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\nThe difference could mean 50,000 to 70,000 fewer deaths and 100,000 fewer cases of kidney failure each year in the U.S., researchers estimate.\nSince there are about 30 million people hospitalized in the U.S. alone each year, \u201cthere are tens or hundreds of thousands of patients who would be spared death or severe kidney problems by using balanced fluids instead of saline,\u201d said one study leader, Vanderbilt\u2019s Dr. Matthew Semler.\nSaline \u2014 salt dissolved in water \u2014 has been the most widely used fluid in the U.S. for more than a century even as evidence has emerged that it can harm kidneys, especially when used a lot.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "In comparing the costs of normal saline vs. balanced fluids, the article states \u201cthe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive.\u201d\nThis is sufficient for a satisfactory rating, but readers should be aware that even a difference of a few pennies per bag would have a significant impact at the institutional level, and a massive impact on the national level.", "answer": 1}, {"article": "Comparing states with and without medical marijuana laws\n\nIn order to evaluate whether medical marijuana could function as an effective and safe alternative to opioids, the two teams of researchers looked at whether opioid prescriptions were lower in states that had active medical cannabis laws and whether those states that enacted these laws during the study period saw reductions in opioid prescriptions.\nThe researchers found that states that allow the use of cannabis for medical purposes had 2.21 million fewer daily doses of opioids prescribed per year under Medicare Part D, compared with those states without medical cannabis laws.\nOne of the studies looked at opioid prescriptions covered by Medicare Part D between 2010 and 2015, while the other looked at opioid prescriptions covered by Medicaid between 2011 and 2016.\nThe two recent studies looked only at patients enrolled in Medicaid and Medicare Part D, meaning the results may not be generalizable to the entire US population.\n\"We saw a 9% or 10% reduction (in opioid prescriptions) in Colorado and Oregon,\" Wen said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not mention how much it costs to use marijuana to treat pain or whether medical marijuana is covered by private health insurance, Medicare or Medicaid.", "answer": 0}, {"article": "Her team of 12, including study co-author and U of A post-doctoral fellow Hein Min Tun, take the science one step closer to understanding the connection by identifying that exposure to pets in the womb or up to three months after birth increases the abundance of two bacteria, Ruminococcus and Oscillospira, which have been linked with reduced childhood allergies and obesity, respectively.\nIn other words, even if the dog had been given away for adoption just before the woman gave birth, the healthy microbiome exchange could still take place.\n\"It's not far-fetched that the pharmaceutical industry will try to create a supplement of these microbiomes, much like was done with probiotics,\" she said.\nA new University of Alberta study showed that babies from families with pets--70 per cent of which were dogs--showed higher levels of two types of microbes associated with lower risks of allergic disease and obesity.\nBut don't rush out to adopt a furry friend just yet.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This is not relevant because we can assume that anyone who owns a dog is likely aware of the cost of housing, feeding and maintaining that animal and those amounts can be quite considerable.", "answer": 2}, {"article": "Caffeine inhibits this circuit and turns the inflammatory pathway off, the researchers say.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\n\u201cThere was no boundary, apparently.\u201d\n\nIn the study, Furman and his colleagues analyzed blood samples from 100 young and old people.\n\u201cThe more caffeine people consumed, the more protected they were against a chronic state of inflammation,\u201d says study author David Furman, consulting associate professor at the Institute for Immunity, Transplantation and Infection at Stanford University.\nIn an upcoming study, Furman and others will soon investigate the immune systems of 1,000 people; he hopes to use that information to develop a reference range of immune-system components to tell people whether their levels are normal, or if they\u2019re at higher risk for developing chronic conditions driven by inflammation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address cost. However, the story focuses almost exclusively on coffee consumption \u2014 and most readers can be assumed to be familiar with the cost of coffee. We\u2019ll rate this as not applicable.", "answer": 2}, {"article": "\u201cC.\n\u201cWhat I like about this paper is that it validates the upper-GI route and demonstrates that you can get very good cure rates without doing a colonoscopy.\u201d\n\nThat\u2019s important because colonoscopies and the anesthesia required for the procedure can put a lot of stress on a person\u2019s body and can be complicated for the people most at risk for C. difficile infections, Hohmann noted\n\nKao\u2019s study also showed that people found FMTs far less unpleasant when the poop came in a pill.\nWhile the FDA said in 2013 that doctors can try fecal transplants in patients with C. difficile infections, the agency noted doctors should only use FMT for other conditions in clinical trials.\nOne recent, small study found that even stool samples that are entirely free of bacteria can be effective, perhaps because there are non-bacterial organisms that also help.\nTwo-thirds of the 57 patients who got the pills said their experiences were \u201cnot at all unpleasant,\u201d while just 44 percent of the 59 patients who received the FMT via a colonoscopy could say the same.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job of pointing out one advantage of the pill approach compared to delivery via colonoscopy\u2013the reduced cost. \u201cThere was a significant difference in cost. Though the procedures were done in a Canadian hospital, the FMTs delivered by colonoscopy cost nearly $500 USD more than the capsules, which cost about $300.\u201d", "answer": 1}, {"article": "CHICAGO (Reuters) - Radiation from CT scans done in 2007 will cause 29,000 cancers and kill nearly 15,000 Americans, researchers said on Monday.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\nA chest CT scan exposes the patient to more than 100 times the radiation dose of a chest X-ray.\n\u201cWe\u2019re doing millions of CT scans every year and the numbers are increasing.\nThe researchers estimated there will be an extra 2,000 excess breast cancers just from CT scans done in 2007.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not\u00a0describe the costs of CT scanning, which are substantial and increasing.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - A fresh look at the medical evidence shows women who eat more fiber are less likely to get breast cancer.\nAnd those in the top fifth of fiber intake were 11 percent less likely to do so than women in the bottom fifth.\nKnown benefits of a high-fiber diet include lower cholesterol and weight loss.\nIf it turns out to cut cancer risk as well, that would be an extra bonus, Clarke said.\nFruits, vegetables, beans, and whole grains are all high in fiber.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of fiber in the diet is not in question.", "answer": 2}, {"article": "\u201cThe high degree of certainty in one report and the extreme caution in the other,\u201d said Rebecca Goldberg, a senior scientist with Environmental Defense, an advocacy group, \u201cwill make people more confused than ever.\u201d\n\nTo the surprise of Institute of Medicine officials, NOAA sponsored the hastily called press conference at which the Harvard report was released, even though that study conflicted with the one prepared by the institute.\nDr. Malden C. Nesheim, chairman of the institute\u2019s committee and a provost emeritus at Cornell, said, \u201cWe are quite cautious because the studies we looked at are not controlled for all the variables, and we can\u2019t distinguish between the effects from omega-3\u2019s or replacement of other foods in the diet.\u201d\n\nThe National Oceanic & Atmospheric Administration had requested the institute\u2019s report because it said consumers were confused about how much and what kind of fish they should eat.\n\u201cAccording to NOAA\u2019s own statistics, per capita consumption of seafood has risen from 14.8 pounds in 2001 to 16.6 pounds in 2004.\u201d\n\nJane Houlihan, the research director of the Environmental Working Group, another advocacy group, said, \u201cThe Harvard study reads like an advertisement for the seafood industry.\u201d\n\nBoth studies reinforce advice from the Food and Drug Administration and the Environmental Protection Agency in 2004, to eat about six ounces of fish a week, preferably high in omega-3\u2019s, with a caveat for women of childbearing age and children under 12 not to eat swordfish, shark, tile fish or king mackerel and to limit their intake of albacore (white meat) tuna to six ounces a week to avoid mercury.\nrecommend.\u201d\n\nDr. Nestle finds the situation so confusing \u201cno rational person can possibly figure out how to make sense of it,\u201d she said.\nFor those who eat more fish, both reports advise eating a variety of species to reduce the level of contaminants.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not report information about the costs of fish (from 63 cents to $2.59 per week, according to the JAMA study), but readers can easily find these on their own if they don\u2019t know them already.", "answer": 2}, {"article": "The visor that allows legally blind people to see is no longer Star Trek fiction.\nPhoto/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\nLeaps in augmented-reality technology are being used to help people with severely low vision gain back enough sight to function, and then some.\nBut when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nGeoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The WSJ reveals that each visor-headset costs $10,000, and even notes how \u201cmost insurance doesn\u2019t cover it.\u201d There\u2019s also some back-and-forth viewpoints about that steep cost, which is helpful to readers.", "answer": 1}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs. However in this context, where the cost of treatment is relatively\u00a0low, this criterion seems less relevant.", "answer": 2}, {"article": "\"Vitamin D supplementation trial in infancy: body composition effects at 3years of age in a prospective follow-up study from Montr\u00e9al\", by T. J. Hazell, S. Gallo, C. A. Vanstone, S. Agellon, C. Rodd, and H. A. Weiler, Pediatric Obesity doi:10.1111/ijpo.12105\n\"We were very intrigued by the higher lean mass, the possibility that vitamin D can help infants to not only grow healthy skeletons but also healthy amounts of muscle and less fat,\" said Hope Weiler, one of the study's authors and Director of the Mary Emily Clinical Nutrition Research Unit at McGill University.\nThe only other factor found to make a significant difference to the children's amount of body fat was their level of physical activity.\nIn addition, Health Canada advises parents and caregivers to avoid direct sunlight and avoid use of sun block creams in young infants.\nThe researchers achieved this by following up on a 2013 study in which 132 infants in Montr\u00e9al, Qu\u00e9bec, were given a vitamin D3 supplement at one of four different dosages between the ages of 1 month and 12 months.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention cost.\u00a0 A quick online search found that the standard infant dose of 400 IU/day of Vitamin D costs about $10-15 for a three-month supply in the United States. We believe news releases should mention costs, including the cost of relatively inexpensive supplements or unusual foods, with associated health claims. Children growing up in poverty are at particular risk of obesity because their families suffer from food insecurity and often purchase the least expensive (and least nutritional) foods. Expenditures for pediatric supplements for people living well below the poverty level may mean less food on the table.", "answer": 0}, {"article": "For more information, please see www.arthrokinex.com\nSignificantly better concentration, healing/pain reduction durability, faster production (just one hour), one-fifth the price, and chemical additive free, IRAPjoint\u2122 is now available in multiple physician practices throughout the United States.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nTypically, the treatment process is painless and just takes a few minutes and consists of one injection per week for three weeks, followed by quarterly injections, as needed.\nThe European-based process was the inspiration for Dr. Barreto of Oklahoma City, Oklahoma to work on developing a stronger, more effective, and more cost-efficient version in the United States.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This news release highlights the cost of the treatment \u2014 $2,000, compared to the price of $10,000 for an unnamed foreign competitor. The New York Times wrote a piece on a company in Germany supplying a similar treatment in 2012 when the cost of the procedure was about $7,500 out of pocket, so the news release seems to be relatively in the ballpark.\u00a0\nAlthough this new treatment may be less expensive that the foreign competitor mentioned, it is likely more expensive than steroid or hyaluronic acid injections and as a non-FDA approved treatment it is unlikely to be covered by American insurance companies.", "answer": 1}, {"article": "Finally, the researchers note, expenses associated with the procedure\u2014the robot costs at least 1.8 million ($2.6 million) to install, 100,000 ($145,000) a year to run, and 1,500 ($2,200) extra for each surgical case-mean the procedure is \u201cprohibitively\u201d expensive \u201cfor many hospitals and indeed many countries.\u201d\n\nThe researchers conclude: \u201cThe significant learning curve should not be understated, and the expense of this technology continues to restrict access to many patients.\u201d\nIn about one in 250 surgeries, the robot failed to work properly.\nYou might want to see a surgeon who has done at least 80 operations for the best results, according to the authors of a new research review.\nThere was also a lack of data on how well patients functioned after surgery, and how patients with high-risk prostate cancer fared long-term.\nBut a US study on nearly 9,000 men published in October 2009 found that while open and minimally invasive surgery were equally good for getting rid of prostate cancer, the risk of incontinence and impotence was higher with the minimally invasive approach.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0The story indicated that the robotic procedure was more expensive than a standard surgical prostatectomy. In addition, it included information about the expenses associated with obtaining and running the equipment.", "answer": 1}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t discuss the cost of what it called the current \"standard of treatment,\" Biaxin, nor the cost of the new drug, cethromycin. If a drugmaker says it is ready to file for new drug approval within a few months, as the story states, you can be assured they have some ballpark estimate of what they expect to charge.\u00a0 The story should have probed for that information. ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study does not mention direct or indirect costs (such as loss of productivity), a significant oversight when comparing surgery to nonoperative treatments. ", "answer": 0}, {"article": "This is something the study\u2019s authors readily acknowledge.\nSeveral of the studies were done in pain centers where they have expert programs, and those just are not widespread.\u201d\n\nIn fact, the lack of access to non-opioid strategies may be one big reason that doctors resorted to opioids in the first place.\nHe added, \u201cI want patients and their doctors to use caution in applying this.\u201d\n\nA few pain patients will still benefit from opioids\n\nOne of the study\u2019s implications is that opioids actually aren\u2019t a good treatment for chronic pain.\n\u201cThere are people who do not do well with tapering.\u201d\n\nBut the study suggests that getting some patients off opioids could improve their pain outcomes.\nFor one, the reviewed studies generally looked at the results of tapering, when patients are slowly weaned off opioid painkillers \u2014 a process that, Stanford psychiatrist Anna Lembke told me, can take months or even years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Tapering is presumably free in and of itself, since it\u2019s a slow and gradual lessening of opioids (which a person might already be using to begin with), so we\u2019ll mark this N/A. However, it would require medical oversight and perhaps other alternative pain treatments, both of which aren\u2019t free.", "answer": 2}, {"article": "\"We would therefore recommend that a future prospective study should be performed to further assess the impact of alcohol consumption on rheumatoid arthritis, a study recording alcohol consumption at the time rather than asking about it later.\"\nAlcohol consumption may also protect people who already have the autoimmune disease from developing a more debilitating form.\nNor do the study authors advise drinking as a cure for arthritis.\nThe association was seen in both men and women, though it was stronger in males.\n\"This actually isn't a new concept.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. The cost of alcohol is not in question. ", "answer": 2}, {"article": "\"There is a growing concern that amyloid is a guilty bystander, but not the actual culprit in the brains of people with Alzheimer's disease, and taking away the bystander may not help the patient,\" he said.\nThere are approximately one dozen therapies, including vaccines, for Alzheimer's disease that are currently in the pipeline, Lyden noted.\nMany in the Alzheimer's research community are awaiting these drugs with bated breath, but \"none are ready for prime time,\" he said.\nThe need for a drug to delay the onset or slow progression of Alzheimer's disease can't be underestimated, Aggrawal said.\n\"They are all extremely exciting and promising in animals,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 It\u2019s understandable that costs wouldn\u2019t be discussed in such early research.", "answer": 2}, {"article": "The study appears in the latest issue of the journal Ophthalmology.\nCompared with the group as a whole, those people who were diagnosed with the eye disease during the following decade were older, had higher blood pressure, and were more likely to be female.\nEarly detection is key, but without regular eye exams, most people don\u2019t know they have a problem, says ophthalmologist Andrew Iwach, MD.\n\u201cWe call this disease a \u2018thief of vision\u2019 because most people with it have no idea that they have lost sight until it is too late to bring it back,\u201d Iwach says.\nAbout 3 million Americans and 60 million people worldwide have glaucoma, and the numbers are projected to rise over the next few decades as the population ages.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t include anything about costs.\nWhat will it cost to use the \u201ccomputer-based imaging tool\u201d described in the story?\u00a0 We\u2019re not told. There is no information on the cost of expanding the use of retinal photographs to a wider population.", "answer": 0}, {"article": "MUSC operates a 700-bed medical center, which includes a nationally recognized children's hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute-designated center), Level I Trauma Center, Institute of Psychiatry, and the state's only transplant center.\nThe 149-bed hospital includes six community based outpatient clinics, a 20-bed nursing home, women's health, and the full range of inpatient and outpatient care, including medical and surgical intensive care.\n\"Addiction goes along with virtually every psychiatric disorder at a higher percentage than it does in the general population\" said Peter W. Kalivas, Ph.D. the senior author on the article and chair of the Department of Neuroscience at MUSC.\nAs the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.2 billion, with an annual economic impact of more than $3.8 billion and annual research funding in excess of $250 million.\nNAC is available over the counter and does not cause side effects at the doses used in the study, but it degrades quickly when stored, is contraindicated in patients with asthma, and can cause nausea at higher doses and so should always be obtained and administered under a physician's supervision.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of N-acetylcysteine although it is on the World Health Organization\u2019s list of essential medicines, is available over-the-counter and is not very expensive. An online search reveals prices ranging from about $6 for 100 capsules containing 600 mg to around $12 for 50 high-dose capsules containing 700 mg.", "answer": 0}, {"article": "This week an unprecedented travel advisory was given for southern Florida after more than a dozen people were diagnosed with Zika after being bitten by \"homegrown\" mosquitoes.\n\"So we\u2019re cautiously optimistic.\u201d\n\nAnd if problems turn up, there are the three potential vaccine described in the new study.\nTrials of that vaccine in people, which is also based on man-made copies of virus proteins, began on August 2, when the first study volunteer was given a vaccination through a needle free injector, said Dr. Anthony Fauci, head of the National Institute for Allergy and Infectious Diseases.\nThe urgency for a vaccine to protect against Zika infection has intensified as the virus spreads rapidly across Latin America and the Caribbean.\nRelated: Company Gets OK to Test New Zika Vaccine\n\nThe researchers gave 16 monkeys an initial dose of ZPIV and then a booster four weeks later.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Putting a cost estimate on experimental vaccines would be difficult to do, so we\u2019ll rate this N/A.\nHowever, there is an\u00a0opportunity in any story about Zika interventions to address the overall costs and financial needs. Congress, for example, has been in the news for months over its failure to earmark funds for Zika control requested by the White House and federal public health officials\u2013how would vaccine funding be affected by that?", "answer": 2}, {"article": "Among randomized controlled trials (RCTs), there was a statistically significant reduction in CHD risk in higher risk populations, including:\n\u2022 16 percent in those with high triglycerides and 14 percent in those with high LDL cholesterol.\n\"The meta-analyses of Alexander and colleagues suggests that omega-3 fatty acid intake may reduce risk of adverse CHD events, especially among people with elevated levels of TGs or LDL-C....omega-3 fatty acid intake of at least 1 gram of EPA+DHA per day, either from seafood or supplementation (as recommended by the American Heart Association), continues to be a reasonable strategy,\" said the authors.\n\"The results confirm that increasing omega-3s is a healthy lifestyle intervention that can contribute towards reductions in CHD risk,\" added Adam Ismail, Executive Director of GOED.\n\"The 6 percent reduced risk among RCTs, coupled with an 18 percent risk reduction in prospective cohort studies -- which tend to include more real-life dietary scenarios over longer periods -- tell a compelling story about the importance of EPA and DHA omega-3s for cardiovascular health.\"\n\"It's also important that the observed risk reductions were even stronger in patient populations with elevated triglycerides and LDL cholesterol levels, two risk factors that affect more than one quarter of the American population.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is only addressed in a quote from the executive director of an omega-3 industry organization, who refers to increasing one\u2019s omega-3 intake as an \u201cinexpensive\u201d lifestyle change. What does \u201cinexpensive\u201d mean? What may be cheap for one consumer could be cost-prohibitive for another. What\u2019s more, it\u2019s difficult for any reader to work out what the cost may be, because the release doesn\u2019t make it easy to determine how much of EPA or DHA one needs to take in order to see any potential benefit. It is only in the tenth paragraph, which quotes an editorial suggesting that taking \u201cat least 1 gram of EPA+DHA per day\u2026continues to be a reasonable strategy.\u201d That\u2019s still not necessarily clear for many consumers, since it\u2019s not directly linked to the benefits discussed elsewhere in the release, but it\u2019s the only reference to how much an individual might need to consume \u2014 and it\u2019s buried near the bottom of the release.", "answer": 0}, {"article": "But she said it\u2019s more convenient and less time-consuming to administer.\nThe federal government\u2019s approval to market the device comes as Alzheimer\u2019s researchers everywhere step up the pursuit for easier and more inexpensive ways to identify dementia in its earliest stages.\nThe 10-minute, non\u00adinvasive examination can detect subtle lapses in the brain\u2019s perceptual ability that may signal the early stages of mental decline caused by dementia.\n\u201cWhat we are all about is making cognitive care part of primary care.\u201d\n\nMore than 5 million Americans have Alzheimer\u2019s disease, the leading cause of dementia.\n[Scientists are cautiously optimistic about progress toward finding treatments for Alzheimer\u2019s disease]\n\n\u201cLook, there is a late-life tsunami of late-life cognitive decline coming at us, and health-care providers are standing on the beach,\u201d said Charles J. Duffy, a neurology professor at the University of Rochester Medical Center who founded the company.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Reporting on any new device, test or drug should include comments about cost.\u00a0 In this case a word or two about the cost of the device, whether or not it is reimbursable under commercial insurance plans or Medicare would have been helpful.\u00a0 There is a billing code used for payment by insurance companies and Medicare (CPT 96120:\u00a0Neuropsychological testing [e.g. Wisconsin Card Sorting Test, CNS Vital Signs], administered by a computer, with qualified health care professional interpretation and report). \u00a0 The reimbursement for the\u00a0test and interpretation is\u00a0$48.\nThe story did mention that other tests can cost more than $1000, but it\u2019s not clear how much less expensive the new test would be. The story also notes that\u00a0the test could be administered without the physician present, which might indirectly cut costs and allow time for other important discussions.", "answer": 0}, {"article": "With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the \"success stories\" of modern cancer treatment.\nThe high-dose methotrexate protocol outlined in the study - along with a parallel finding that the steroid decadron is beneficial for younger (but not older) patients - has quickly become the standard practice for the treatment of high-risk ALL patients in North America, the researchers report in the April XX issue of the Journal of Clinical Oncology.\n\"One of the improvements in outcome for ALL overall has been using methotrexate in a more intense fashion, by giving higher doses,\" said senior investigator William L. Carroll, MD, the Julie and Edward J. Minskoff Professor of Pediatrics, director of the Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders at NYU Langone and director emeritus of NYU Langone's Perlmutter Cancer Center.\n\"The improvement in cure rates for ALL over the last few decades, for the most part, has not come through the introduction of new medications, but through using existing medications in new ways, in terms of their dose and schedule,\" Dr. Carroll said.\nDecadron, however, can increase the infection rate, particularly in high-risk ALL patients, when given for the full 28-day induction period.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release makes no mention of the costs of the drugs compared in this study, even though the drugs have been in use for years and are widely available.\u00a0 Since the study is a comparison of various treatments for this form of cancer, it seems relevant to offer a cost comparison as well as a comparison of efficacy. It appears that the high dose methotrexate is given over a 24-hour period, presumably in the hospital, while the standard methotrexate is given as a single dose.\u00a0 Also, the high dose methotrexate is\u00a0followed by leucovorin administration while the standard dose is not.\nAccording to the site GoodRx, the cost for methotrexate in low-dose (2.5 mg) pill form averages out to about $50 for a month\u2019s supply. Newer, injectable variations of the drug cost upwards of $500 a month for the 25 mg dose.", "answer": 0}, {"article": "The comparison groups in the experiments varied as well.\n\"The onus is back to researchers to carry out studies that would stand up\" to rigorous review and that would build on what's already been tested.\nThe medicine, though never approved for use in the United States, led to birth defects in some 10,000 kids in Europe and Canada.\nMorning sickness is quite common, with most pregnant women getting nauseous early on and around a third throwing up.\nAnd here's a biggie: There wasn't much information about adverse effects on women and babies, something everyone would certainly want to know.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There wasn\u2019t any discussion of\u00a0costs of these treatments. The point of the story was tell readers that these treatments couldn\u2019t be recommended on the basis of medical evidence. Even in an overview of available treatments, some cost information is important for readers, especially given the fact that regular acupuncture treatments are going to cost a lot more than vitamin B-6. How much money are people wasting on these treatments?", "answer": 0}, {"article": "For more information, visit http://www.\nLeesburg, VA, March 13, 2018 - When compared to the screening population ages 50 and over, screening mammography in women ages 40-49 detects 19.3% additional cancers at the expense of an overall 1.5% increase in callbacks and 0.1% in increased biopsies, according to a study to be presented at the ARRS 2018 Annual Meeting, set for April 22-27 in Washington, DC.\nThe study results showed that there was a higher number of callbacks among women ages 40-49 compared to women ages 50-59 (17% compared with 12.5%) and to women ages 60-69 (17% compared with 10.2%).\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\nWith educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2018 Annual Meeting, April 22-27, at the Marriott Wardman Park Hotel in Washington, DC.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are a huge part of the controversy on when to begin breast cancer screenings. This news release doesn\u2019t mention the cost of mammograms, but they can be substantial. One study published in the Annals of Internal Medicine found that in terms of cost-effectiveness, it was five times more cost effective to do mammograms on women over the age of 50 than women aged 40-49. This is because while the costs of mammograms stay the same, the incidence of disease is much lower in the 40-49 age group.", "answer": 0}, {"article": "What is the effect of Topical Curcumin Gel for treating burns and scalds?\nIn recent years, the medicinal value of curcumin has been the subject of intense scientific studies, with publication numbering in the thousands, looking into the possible beneficial effects of this natural product on many kinds of affliction in humans.\nIn a recent research paper, published in the open access journal BioDiscovery, Dr. Madalene Heng, Clinical Professor of Dermatology at the David Geffen School of Medicine, stresses that use of topical curcumin gel for treating skin problems, like burns and scalds, is very different, and appears to work more effectively, when compared to taking curcumin tablets by mouth for other conditions.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\n\"Curcumin gel appears to work much better when used on the skin because the gel preparation allows curcumin to penetrate the skin, inhibit phosphorylase kinase and reduce inflammation,\" explains Dr Heng.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Since there is no discussion of costs in the news release, we give it a Not Satisfactory rating here.\nA Google search reveals that curcumin gel is available for purchase, mostly in natural food stores and through alternative medicine websites. A 2-oz tub of \u201cCurcumin Gel For Face And Body\u201d from Omnicure sells for about $89. Topical curcumin is also available as a cream, in which a 4-oz. bottle goes for $44.95.\nOther companies also market and manufacture topical curcumin gel, but the researcher in this study owns Omnicure shares (see our conflict of interests section).", "answer": 0}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs, and this is an important oversight considering how expensive inpatient surgery is. Presumably this fast-track surgery is less expensive since it reduces time spent in the hospital, but we\u2019re not giving any specifics.", "answer": 0}, {"article": "But even that can be helpful.\n\"There's been a substantial uptick in the amount of research,\" said Marshall Plaut of the National Institute of Allergy and Infectious Diseases, which has more than doubled the funding for food-allergy research since 2007.\nIt remains far from clear, however, what proportion of children will benefit, how long the benefit might last and what proportion will need to continue to consume at least some milk or peanuts every day to maintain their protection.\n\"There's definitely been a spike in the amount of work going on,\" said Hugh A. Sampson, a professor of pediatrics, allergy and immunology at the Mount Sinai School of Medicine in New York who leads a federally funded consortium studying food allergies.\n\"It's a way of sort of rerouting or tricking the immune system to no longer be allergic to that food,\" said Stacie Jones, chief of allergy and immunology at the Arkansas Children's Hospital, who has been working Burks to test the approach for peanut allergies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t mention any potential costs, but it did make clear that these were small, early studies.\u00a0 So it\u2019s understandable that costs aren\u2019t yet known.\u00a0 Nonetheless, we wish the story would just say that \u2013 and make the safe prediction that since this treatment will involve multiple visits over a protracted period the costs will likely not be inconsequential.\u00a0", "answer": 2}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nThe randomized controlled trial shows superior outcomes in patients undergoing minimally invasive sacroiliac joint (SIJ) fusion using triangular titanium implants, compared to nonsurgical management, according to the new research overseen by Dr. Daniel J. Cher of SI-BONE, Inc., in San Jose, Calif. (The study was sponsored by SI-BONE, manufacturer of the SIJ implants.)\nGood Pain Relief and Other Outcomes with Implant Treatment for SIJ Dysfunction\n\nThe study included 148 patients with low back pain caused by confirmed SIJ dysfunction, treated at 19 US spine surgery clinics.\nThe authors note some important limitations of the trial, including the lack of long-term outcomes in the nonsurgical group due to the high crossover rate.\nThe implant procedure is minimally invasive, has few complications, and produces significant and lasting improvements in pain, disability, and quality of life.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t discuss costs for the implant procedure. Although \u201cminimally invasive,\u201d surgical treatment options can still run into tens of thousands of dollars. Not all insurance providers cover SJF procedures. Some cover it for certain conditions but not others. The procedure was recently approved for coverage by Medicare and by Medicaid in some states.", "answer": 0}, {"article": "\u201cWho doesn\u2019t want to maximize their cognitive ability?\nThat\u2019s because when you up one circuit in the brain, you\u2019re probably impairing another system.\u201d\n\nEarly studies attributed a lot of short-term benefits to nootropics \u2014 so much so that in 1983, Russian scientists turned to phenylpiracetam to boost the physical and mental performance of cosmonauts during space flight.\n\u201cThere\u2019s a sizable demand, but the hype around efficacy far exceeds available evidence,\u201d notes Doraiswamy, adding that, for healthy young people such as Silicon Valley go-getters, \u201cit\u2019s a zero-sum game.\n\u201cIt\u2019s the few who are getting ahead who are using supplements to do that.\u201d\n\nThe word \u201cnootropic\u201d was coined in 1972 by a Romanian scientist, Corneliu Giurgea, who combined the Greek words for \u201cmind\u201d and \u201cbending.\u201d Caffeine and nicotine can be considered mild nootropics, while prescription Ritalin, Adderall and Provigil (modafinil, a drug for treating narcolepsy) lie at the far end of the spectrum when prescribed off-label as cognitive enhancers.\nAs Plato is said to have stated, \u201cI fast for greater physical and mental efficiency.\u201d The philosopher Pythagoras reportedly demanded that his students fast 40 days before attending his lectures.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of cost. We found one drug cited in this story \u2014 piracetam \u2014 online for $39.99 for 180 capsules. For those seeking a cocktail of supposed brain boosters, startup Nootrobox charges $135 for \u201call the nootropics you need to enhance your cognitive state for one month.\u201d The company explains: \u201cCognitive performance is an active, long-term investment.\u201d\n(Notably, piracetam isn\u2019t on Nootrobox\u2019s ingredient list. For more on that, read the section on availability.)", "answer": 0}, {"article": "Yet the study suggests the opposite has happened.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nThe study found that among all opioid users, concurrent use of benzodiazepines more than doubled the risk of an emergency room or inpatient visit for a drug overdose.\nBut there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\nThe study also found that eliminating concurrent benzodiazepine and opioid use could reduce the risk for an opioid overdose\u2013related emergency room or inpatient visit by 15 percent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the cost implications may be murky, the story should have at least broached the topic. Changing treatment strategies for thousands of patients could reduce costs if patients drop medications without replacing them or increase costs if patients switch to more expensive therapies. Certainly, keeping people out of ERs and hospital beds would be a savings, but it also would\u00a0cost money to transition people off these medications and use different treatments, such as therapy sessions.", "answer": 0}, {"article": "MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute designated center) Level I Trauma Center, and Institute of Psychiatry.\nIt is also not clear how the device would work for patients with cranial implants, as metal interferes with the device's operating radio frequencies.\nYet the consultants did not have access to the VIPS radio wave data during their review of the images, thereby eliminating the potential of the consultants to choose data that might artificially inflate the device's accuracy.\nThe researchers hope that the device will save valuable time -- especially important in stroke where time is brain -- when it is deployed with emergency medical personnel in the field.\nIn their next steps, the researchers are undertaking the VITAL 2.0 study to determine if the VIPS device can use complex machine learning algorithms to teach itself how to discriminate between minor and severe stroke without the help of neurologists.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Even though the device is still in its testing phase, not discussing what the ultimate cost could be does a disservice to readers.", "answer": 0}, {"article": "However, they say these findings \u201craise questions that warrant investigation\u201d and call for verification in randomised studies \u201cbefore recommending a change to current practice.\u201d\n\nNotes to Editors\n\n Research: Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: population based cohort study\n\n Journal: The BMJ\nMore boys are diagnosed with the condition than girls.\nThere was no consistent evidence that either iron or folic acid use were associated with a reduced risk of ASD.\nHowever strengths included the relatively large population-based sample size and the advanced analytical methods used to gauge the robustness of findings.\nIt\u2019s estimated that about 1 in every 100 people in the UK has ASD.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release did not mention costs of vitamin supplements.", "answer": 0}, {"article": "For more information, visit http://www.\nMoreover, the consumption of one medium fresh pear per day had a positive effect on nutrient intake since consumers had higher usual intakes of dietary fiber, vitamin C, magnesium, copper, and potassium, and higher mean intakes of total sugars; consumers of fresh pears also had lower intakes of total, monounsaturated fatty acids, saturated fatty acids, and added sugars.\nA new study, 'Fresh Pear Consumption is Associated with Better Nutrient Intake, Diet Quality, and Weight Parameters in Adults: National Health and Nutrition Examination Survey 2001-2010,' published in Nutrition and Food Science, revealed new information regarding the health benefits of pear consumption.1 Of particular interest given the high rates of obesity in the United States, the study found that adult pear consumers had a lower body weight than non-pear consumers and they were 35 percent less likely to be obese.\nA nationally representative analytic sample suggests that the consumption of fresh pears should be encouraged as part of an overall healthy diet\n\nPORTLAND, Ore. - Dec. 8, 2015 - It's National Pear Month and the perfect time to enjoy juicy, sweet pears.\nPears are an excellent source of fiber and a good source of vitamin C. One medium pear provides about 24 percent of daily fiber needs for only 100 calories.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "If consumers are encouraged to eat a pear a day it would be helpful to include even a ballpark cost. Fresh pears may be available in all markets year-round but the cost rises substantially when they have to be shipped long distances.", "answer": 0}, {"article": "NEW YORK (Reuters) - Johnson & Johnson\u2019s Stelara helped a significantly higher percentage of Crohn\u2019s disease sufferers than those who received a placebo, according to a study of patients who had not been helped by other commonly used drugs.\n\u201cThey\u2019ll feel measurably better.\u201d\n\n\u201cThe patient population was really quite ill and had very high disease activity, and despite that we saw nice response rates,\u201d Sandborn said.\n\u201cTo see these kind of outcomes, where you have high response rates in the short term and then good remission rates out toward five or six months of therapy, it shows unequivocally that the drug is effective for treating Crohn\u2019s disease,\u201d said Dr. William Sandborn, the study\u2019s lead investigator, who presented the data at the Digestive Disease Week meeting in Chicago on Sunday.\n\u201cIt\u2019s effective in the patient population that has the greatest unmet need at this point in time,\u201d Sandborn said of patients who do not respond to anti-TNF drugs.\nAfter 22 weeks, 69.4 percent of the Stelara patients maintained a clinical response and 41.7 percent were deemed to be in clinical remission.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While we\u2019re given the size of the market, we don\u2019t get the costs of the drug itself. It\u2019s a biologic treatment and it ain\u2019t cheap.\u00a0 Even if this story is targeted at a business audience, patient costs are extremely relevant.", "answer": 0}, {"article": "Cosette Wheeler, PhD, at The University of New Mexico Comprehensive Cancer Center, was the lead author of the report.\nThrough its partnership with the New Mexico Cancer Care Alliance, an \u201cexemplary national model for cancer health care delivery,\u201d the UNM CCC offers access to more than 175 clinical trials to New Mexicans in every part of the state.\nNewswise \u2014 WhatA research paper published in The Lancet Infectious Diseases reported that the human papillomavirus (HPV) vaccine is safe and efficacious across a wide age range of women.\nWhenThe paper, \u201cEfficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study,\u201d was published in the June 28, 2016 online edition of The Lancet (www.thelancet.com/infection).\nOne of the premier cancer centers nationwide, the UNM CCC has more than 125 board-certified oncology physicians, forming New Mexico\u2019s largest cancer care team.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The vaccine is expensive and requires three, possibly in the future two, doses. Insurance may not cover it since it is not currently recommenced for the age group studied.\n\u201cThe drug company price for either vaccine is around $130 or $140 per dose,\u201d according to the American Cancer Society, \u201cThis cost does not include the cost of giving the shots or the doctor\u2019s charge. So, it\u2019s possible that the cost for the series (3 shots over 6 months) could be $500 or more.\u201d", "answer": 0}, {"article": "Her report is the latest warning from researchers who suspect that stents are being overused and may even be causing heart attacks and deaths.\nIt can be helpful in people who are still suffering from chest pain or have certain other complications from the heart attack.\nIn that situation, the procedure is called late angioplasty.\nThe new study tried to determine if late angioplasty could help them.\nThe study did not address the use of angioplasty and stents in people who have not had heart attacks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0The estimated cost for having a stent placed in a coronary artery was mentioned.", "answer": 1}, {"article": "Thanks to members Drs.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\nThe lifetime risk of suffering symptomatic knee OA is estimated to be 44.7% and approximately 1 in 11 of the US population is diagnosed with symptomatic knee OA by age 60.\nWith this knowledge, the American Medical Society for Sports Medicine (AMSSM) has released a new scientific statement that provides guidance for physicians and healthcare professionals who provide care for those patients with knee osteoarthritis.\nNewswise \u2014 LEAWOOD, KS \u2014 Osteoarthritis (OA) is one of the leading causes of disability in adults in the United States and knee OA specifically is ranked within the top 10 non-communicable diseases for global disability-adjusted life years.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Given the statistics on the incidence of osteoarthritis of the knee provided in the release, the cost of viscosupplementation is important. The costs of the material (technically, hyaluronic acid derivatives are medical devices) varies depending on which is chosen but costs range between $300 to $500 per injection. \u00a0Since osteoarthritis of the knee is a chronic condition, the durability of the injection is an important aspect of costs. Clinical trials suggest that when it is effective, the duration is varied ranging from weeks to up to six months.\nAccording to the American Academy of Orthopedic Surgeons web page, an organization that does not specifically endorse viscosupplementation, \u201cIf the injections are effective they may be repeated after a period of time, usually 6 months.\u201d", "answer": 0}, {"article": "Microsoft stresses that Emma Watch is not a cure for the disease, which afflicts 10 million people.\nThe watch works through a combination of sensors and AI (artificial intelligence) techniques to potentially detect and monitor symptoms like tremors, stiffness and instability, among others, according to Microsoft.\nWorking with graphic designer and Parkinson's sufferer Emma Lawton, 32, the researchers developed a watch \u2014 which they named Emma \u2014 that, according to Microsoft, \"vibrates in a distinctive pattern to disrupt the feedback loop between brain and hand.\"\nBut at Build 2017 in Seattle Wednesday, Microsoft went for the waterworks at the conclusion of CEO Satya Nadella's keynote address: it showcased a prototype watch that temporarily eliminated the arm shaking that often plagues those suffering from the neurological disease Parkinson's.\nEmma Watch remains a prototype, Microsoft says, but the developers are working with a neuroscience research team to undertake trials with a small group of Parkinson's sufferers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No\u00a0price is discussed, but since it\u2019s made clear that the \u201cEmma\u201d watch is a one-off prototype, we\u2019ll mark this one as \u201cnot applicable.\u201d However, it would have been useful to mention the price range of smart watches.", "answer": 2}, {"article": "Gerdes has published 32 animal studies showing a link between improvements in thyroid hormone levels and heart health in rats and mice.\nIn the study entitled \"Long-term physiological T3 supplementation in hypertensive heart disease in rats,\" aging female rats with hypertension progressing to heart failure were treated for one year (half their lifetime) with a low oral dose of the active form of thyroid hormone, T3.\n\"What we have tried to do here is show the effect of safe doses of thyroid hormones and we're seeing amazing results in multiple studies, with dramatic improvements in heart function, gene expression, and collagen levels, just by restoring depressed thyroid levels in the heart,\" said Gerdes.\n\"This low dose of thyroid hormone safely restored depressed cardiac tissue T3 levels to normal while largely preventing the accumulation of collagen, or scar tissue, resulting from sustained high blood pressure,\" said Gerdes.\nThyroid hormones administered to female rats with high blood pressure led to encouraging cardiac improvements, according to a study in the American Journal of Physiology led by NYIT College of Osteopathic Medicine researcher Martin Gerdes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release is reporting on work done in an animal model, far removed from clinical use in humans. As such, it would be virtually impossible to tell readers precisely how much potential treatment might cost consumers. And so we won\u2019t ding the story for not including a discussion of costs \u2014 we\u2019ll rate this Not Applicable.\nThat being said, it wouldn\u2019t have been difficult to discuss costs in general. T3 is not a new drug. For example, combinations of T3 and thyroxine (another thyroid hormone) are prescribed to patients with hypothyroidism or thyroid cancer. The release could have mentioned that versions of T3 are already on the market and discussed cost at least in general terms. Is it relatively inexpensive? Expensive?", "answer": 2}, {"article": "For more information about our products and the organization, visit http://www.\nJanuary 30, 2018 - For older women undergoing mastectomy for breast cancer, direct-to-implant (DTI) breast reconstruction provides good outcomes in a single-step procedure, while avoiding some of the inconvenience and risks of staged approaches to breast reconstruction, reports a study in the February issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nThe researchers emphasize that DTI isn't an option for every patient, depending on breast shape and other factors.\nThe company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.\nThe researchers believe the DTI technique may expand the options for older women, who are less likely to undergo breast reconstruction.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This news release doesn\u2019t mention the cost of either the new approach being studied (direct-to-implant, or DTI, breast reconstruction) or the widely used tissue expander/subsequent implant approach to which it\u2019s compared.\nIt also made no mention on whether Medicare would cover either procedure.  ", "answer": 0}, {"article": "The drug used in the study was manufactured by Organix Inc. in Woburn, Mass.\nHe also says \u201cPsilocybin therapy may not work for everyone, and some groups, such as people with schizophrenia, as well as adolescents, should not be treated with it.\u201d\n\nBoth the NYU Langone and Johns Hopkins studies were principally funded by the Heffter Research Institute, a non-profit, scientific institution with the principal mission of helping to design, review and fund studies on the use of psilocybin for a wide range of ailments (Ross previously served as a board member).\n\u201cAnd if it\u2019s true for cancer care, then it could apply to other stressful medical conditions.\u201d\n\nBossis cautions that patients should not consume psilocybin on their own or without supervision by a physician and a trained counselor.\n\u201cOur results represent the strongest evidence to date of a clinical benefit from psilocybin therapy, with the potential to transform care for patients with cancer-related psychological distress,\u201d says study lead investigator Stephen Ross, MD, director of substance abuse services in the Department of Psychiatry at NYU Langone.\nFor the study, half of the participants were randomly assigned to receive a 0.3 milligrams per kilogram dose of psilocybin while the rest received a vitamin placebo (250 milligrams of niacin) known to produce a \u201crush\u201d that mimics a hallucinogenic drug experience.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release refers to psilocybin as being \u201cinexpensive,\u201d if and when it were to become a clinical treatment option. However, there is no basis provided for why the drug would be inexpensive or what that means relative to other treatments. Given that it is currently a banned substance, it\u2019s difficult to assess how expensive the drug would be \u2014 or in what clinical circumstances it may be used (which could affect the cost for patients).\nYou may be wondering, \u201cHow can the release further address cost, given that the relevant drug is a banned substance?\u201d One way would be to specifically note that it is difficult to estimate what the cost of psilocybin treatment would be, given that it is currently a banned substance.", "answer": 0}, {"article": "Yet, the researchers' risk assessment questionnaire was equally poor.\n\"If you think about your car, you have to run your gas tank all the way down before the red light goes on, and that's similar to the way we're screening for iron deficiency,\" said Deepa L. Sekhar, physician and associate professor of pediatrics.\nHowever, the only risk factor significantly associated with iron deficiency without anemia in young women in this study was having had a period for more than three years.\nThe researchers then looked at potential iron deficiency risk factors in this group, including the age when they started menstruating, as well as their race and ethnicity, poverty status, food insecurity, tobacco or nicotine use, dietary information, body mass index (BMI) and physical activity.\nIn addition to timing, further research will be needed to determine which blood test for iron deficiency without anemia is accurate, cost-efficient and practical for routine doctor's office use.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release mentions that existing hemoglobin tests are affordable, but that screening for iron-deficiency below the level of anemia can be costly. This squeaks by as discussing \u201ccosts\u201d but we wish figures had been offered. Is affordable $2 or $20? Is costly $100 or $500? Numbers would help readers better understand the cost implications of screening.", "answer": 1}, {"article": "Armed with her previous research, Bahn and her team detailed a panel of blood biomarkers in individuals who have an increased risk of schizophrenia but have no visible symptoms yet.\n\u201cAs the development costs of a test are very high, there is a risk that the test will not be commercially viable.\u201d For severe mental illnesses like schizophrenia, it\u2019s also the case that even if a test made it through development and hit the market, it may not be successfully integrated into psychiatric practice.\n\u201cThe problem with schizophrenia is that although about 1 percent of the population suffers from schizophrenia, the number of new patients per year is quite low, at 0.02 percent,\u201d says Bahn.\nNow some believe the key may be realizing that mental illnesses are not necessarily contained in the brain: Biomarkers may be found throughout the entire body.\nThe test, says Bahn, can accurately predict whether someone will \u201cdevelop schizophrenia over the next two years.\u201d\n\nBahn\u2019s finding is one of several recent advancements toward a comprehensive system of biological mental health diagnostic tools.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in this piece. With the variety of tests that are being discussed, it would have been possible to at least mention a range of possible costs per test.", "answer": 0}, {"article": "Before undergoing surgery, cancer patients could be given the Zika vaccine to \"let the viruses hunt down the GSCs [glioblastoma stem cells] and eliminate them,\u201d said virologist Dr. Cheng-Feng Qin of the Chinese Academy of Military Medical Sciences in Beijing, who worked on the study.\nShi said: \u201cScientists may turn the 'bad' side of a devastating pathogen\u2014Zika virus\u2014for potential cancer therapy.\u201d\n\nHowever, he cautioned any potential treatment which could emerge from the study is far from being rolled out.\n\u201cFor example, we need to make sure that the therapeutic vaccine virus does not infect and kill normal neurons in humans.\u201d\n\nDr. Harry Bulstrode, brain tumor expert funded by the charity Cancer Research U.K. who is researching how Zika could be used to treat aggressive brain tumors, who was not involved in the study, told Newsweek: \"This study is another interesting piece in the jigsaw, but it is never going to demonstrate what we believe to be the really exciting properties of the virus.\nHowever, as the disease spreads, it becomes difficult to differentiate healthy brain cells from cancerous glioblastoma stem cells, and the condition is therefore almost impossible to completely remove.\nThe study showed that a live-attenuated Zika vaccine (containing a weakened version of the virus that does not cause disease in humans) could selectively infect and kill human glioblastoma stem cells, explained Shi.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a report of the results of a clinical trial in mice. It\u2019s too early to estimate costs for human treatment. However, some discussion of the steep, sometimes bankrupting, costs of cancer treatment is always a good idea.", "answer": 2}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t provide any cost estimate for candesartan. It did mention that there was a need to conduct analysis examining the risk to benefit ratio including costs.", "answer": 0}, {"article": "Noctiva is taken daily, approximately 30 minutes before going to bed.\n\u201cIt is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.\u201d\n\nNocturia (wakening at night to urinate) is a symptom that can be caused by a wide variety of conditions, such as congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate.\nAlthough these trials showed a small reduction in the average number of night-time urinations with Noctiva compared to placebo, more patients treated with Noctiva were able to at least halve their number of night-time urinations, and patients treated with Noctiva had more nights with one or fewer night-time urinations.\nThe U.S. Food and Drug Administration today approved Noctiva (desmopressin acetate) nasal spray for adults who awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the night).\n\u201cToday\u2019s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate,\u201d said Hylton V. Joffe, M.D., M.M.Sc., director of the Division of Bone, Reproductive, and Urologic Products in the FDA\u2019s Center for Drug Evaluation and Research.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The FDA evaluates drugs without considering the cost, which is why we give the release a pass for not mentioning the price tag. We hope the FDA could one day also comment on the projected cost of drugs and their cost-effectiveness.\nHow much will this re-purposed drug cost? We found a 5-milliliter bottle of generic desmopressin acetate on the market for $69.95. However, the manufacturer that won approval for this new use might charge significantly more when it markets the drug under the name Noctiva. The company had no comment on pricing, according to a recent report in FiercePharma.", "answer": 2}, {"article": "Grob said the pilot study proved the drug could be studied safely in cancer patients.\nThese compounds were associated with a very politically active counterculture,\u201d said Dr. Charles Grob of Harbor-University of California Los Angeles Medical Center and the Los Angeles Biomedical Research Institute.\nResearchers said the studies were abandoned in the early 1970s when hallucinogenic drugs such as LSD \u2014 lysergic acid diethylamide \u2014 became widely used on the streets, leading to strict federal laws regulating their use.\nIf it proves effective among late-stage cancer patients, U.S. regulators would need to make special accommodation for its use, Grob said.\nDuring the placebo phase, each of the 12 patients received a dose of niacin \u2014 a vitamin that raises levels of good cholesterol \u2014 and given the same instructions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There would have been two ways to approach costs in this case. The first would be to ask\u00a0local, state or federal law enforcement sources for\u00a0ballpark estimates of the street value of the drugs involved. The second would be to ask the researchers how much they spent to obtain the drugs.", "answer": 0}, {"article": "Another sensor, just approved by the F.D.A.\nI also had three sensor catheters slip out and require early replacement, which would be especially annoying to anyone paying the $35 that each sensor costs; I wasn\u2019t, because MiniMed had supplied everything free for testing, but everybody else will, since the sensors are not yet covered by insurance.\nIt has to be placed above the hip or the buttocks, which makes reaching it awkward, and then the wire leading from the sensor has to be connected to a transmitter that wirelessly sends the information to the pump.\nand made by DexCom, is said by some researchers to be a bit more accurate, as is a third device, from Abbot, which has not yet been approved.\nThe device, made by Medtronic MiniMed, is called the Paradigm Real-Time, a combination insulin pump and continuous glucose sensor.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does describe monthly testing supply costs for the new device ($350). However, the article could be improved by telling readers how much the actual device costs and/or comparing this to typical blood glucose testing monitors and supplies. ", "answer": 1}, {"article": "The research described in Quick Study comes from credible, peer-reviewed journals.\nThe study involved 416 adults (average age, 37) who had gone to an emergency department with an extremity injury causing moderate to severe pain (averaging 8.7 on a scale of 1 to 10).\nEven for people who initially had rated their pain as a 10 (for the worst pain possible) or had broken a bone, there was virtually no difference in pain reduction between those who had and had not taken an opioid.\nResearch has shown that even short-term opioid use, such as that stemming from an initial prescription for pain from an injury or surgery, can make people predisposed to a dependence on the powerful drugs \u2014 partly from their effectiveness at relieving pain and partly from the euphoria they produce.\nThe drug industry\u2019s triumph over the DEA, even as opioid-related deaths rise\n\nShingles can be intensely painful; it may also mean health problems ahead\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t addressed. As we noted when reviewing the news release, the costs of ibuprofen and acetaminophen are fairly low \u2014 but the relevant opioids are also relatively inexpensive. For the relevant dosages, the costs would be more or less comparable, with the hydrocodone/acetaminophen combination likely being the most expensive.", "answer": 0}, {"article": "(CNN) -- The use of mammograms has dipped since a medical task force made controversial recommendations that women in their 40s may not need to get breast cancer screenings every year, according to one of three small studies to be presented Monday.\n\"There are whole lots of assumptions that are not supported by the data they presented.\"\nIt's obvious that annual screenings would catch cancers before they progress, she said.\n\"This is a decision that should belong to the woman with appropriate info on hand.\"\nThe task force did not say don't get mammograms, Moyer said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At some point, costs must enter into this discussion.\u00a0 But this story never got there.", "answer": 0}, {"article": "Our research shows for the first time that mefenamic acid, a simple [NSAID] can target an important inflammatory pathway called the NLRP3 inflammasome, which damages brain cells,\u201d David Brough, lead author of the study said, in a statement.\nResearchers, who conducted the study on mice, found that mefenamic acid \u2014 a common Non-Steroidal Anti Inflammatory Drug (NSAID) used to relieve menstrual pain \u2014 can completely reverse memory loss and brain inflammation that are hallmark changes of Alzheimer\u2019s, which currently affects over five million Americans.\nBut, they also warned that these \u201cdrugs are not without side effects and should not be taken for Alzheimer\u2019s disease at this stage - studies in people are needed first.\u201d\n\nThe research was published in the journal Nature Communications on Thursday.\nAlzheimer\u2019s disease, the most common form of dementia, can be fully cured with an anti-inflammatory drug commonly used for period pain, a new research by the University of Manchester shows.\nBecause this drug is already available and the toxicity and pharmacokinetics of the drug is known, the time for it to reach patients should, in theory, be shorter than if we were developing completely new drugs,\u201d Brough said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs don\u2019t rate a mention in the story.\u00a0The drug in question requires a prescription in the United States and is expensive, ranging between $111 and $400 for a 30-day course of treatment.", "answer": 0}, {"article": "This study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\nEven though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\nThe findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.\n\"We hope to confirm these results in a larger prospective randomized trial that is underway now at Yale during the 2015-2016 flu season.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t mention any costs associated with the high-dose vaccine.\nThe New York Times reported last year that \u201cThe cost of the high-dose vaccine is $28.65 a dose, and Medicare covers one shot a year without a co-payment.\u201d", "answer": 0}, {"article": "The most dangerous type, melanoma, occurs in about 73,000 people in the U.S. each year and kills more than 9,900.\nOne patient who could benefit from the vitamin treatment is Charity Wiese, who has been diagnosed with skin cancer more than two dozen times in the last five years.\n\"If you can reduce the new skin cancer rates for these patients, it would be an enormous benefit,\" she told CBS News.\nNearly 5 million people are treated for skin cancer in the U.S. each year, and the Skin Cancer Foundation says 1 out of 5 Americans will develop skin cancer in their lifetime.\n(Another popular form of Vitamin B3 called niacin was not used in this study.)\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019re told right off the bat that twice-daily nicotinamide supplements cost about $10 a month.", "answer": 1}, {"article": "While Drs.\nWhile the FAME 2 trial showed that PCI reduced urgent hospital admissions and revascularizations and likely reduced heart attacks, it did not provide evidence for a difference between PCI and medication alone in the prevention of deaths.\nIn situations where the heart's arteries narrow less suddenly and do not cause a heart attack but induce chest pain during exercise - a condition known as stable coronary artery disease - it has remained unclear whether PCI in addition to medication was better than medication alone in preventing future heart attacks.\nPublished today in the New England Journal of Medicine and simultaneously presented at EuroPCR 2018 in Paris, France, the five-year analysis of the FAME 2 trial shows that initial PCI along with medication was associated with a significant reduction in urgent hospital admissions and revascularizations to restore blood flow in the blood vessels of the heart and a likely reduction in heart attacks as compared to medication as the only treatment.\nThe medication used in the FAME 2 trial consisted of a combination of aspirin, cholesterol-lowering and blood pressure-lowering drugs as required by current treatment guidelines.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address the cost of adding PCI to standard medical therapy. Nor does it mention the hypothetical cost savings that might accrue from avoiding hospitalizations in patients whose PCI procedures help avert heart-related complications.", "answer": 0}, {"article": "I took her to somebody who supposedly could heal through touch,\u201d she said.\n\u201cThe easiest way to get their brain to become coordinated is by making their body coordinated, so a large part of what we're doing is this sensory motor interaction, building their muscle tone, building their strength, building their body spatial awareness.\u201d\n\nThe program also incorporates what Melillo calls \u201cbionutritional\u201d guidelines to make sure children are getting the proper nutrition for optimal learning.\n\u201cAnd if [kids] have poor coordination in their body, they often have poor coordination in their brain -- poor coordination between their networks -- so they can't bring all these networks together to learn in the most optimal way.\u201d\n\nThe program uses a combination of sensory motor (physical) exercises and academic learning to help stimulate and strengthen the parts of the brain responsible for certain disorders.\n\u201cShe would wake up in the middle of the night with night terrors at a very young age, she stopped napping around 15 months \u2026 any type of change in our schedule could set off an epic tantrum.\u201d\n\nOakes didn\u2019t know it then, but her daughter Mallory was one of more than 10 percent of American children living with attention deficit hyperactivity disorder (ADHD)\n\n\u201cShe was diagnosed in first grade after there were some difficulties in the classroom,\u201d Amy said.\n\u201cI thought we weren't going to get accepted to the program, and they told us they could help us and we never looked back.\u201d\n\nThe specialized learning centers, of which there are now 80 throughout the country, were developed by Dr. Robert Melillo, a neurology researcher and author of the book \u201cDisconnected Kids,\u201d to help balance the brains of kids with learning disorders, like Mallory.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not include any mention of costs. Typically taking a child out of the home to attend any kind of face-to-face training for learning differences can be expensive. The story does not give us any idea what visits to Brain Balance Achievement Centers cost, or how many visits a typical family would make.\u00a0According to a news story\u00a0written about the franchised national chain, a typical course of therapy cost about $6,000 in 2010.", "answer": 0}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are no mentions of costs in the piece. Ordinarily, we expect to see some discussion of what the cost may be\u2013especially when Wall Street is closely watching the drug\u2019s progress. In this case, however, the story makes it abundantly clear that the results were lackluster and so this drug is unlikely to be on the marketplace anytime soon.", "answer": 2}, {"article": "Patients played the role of cab drivers who picked up passengers and delivered them to one of six requested shops in the city.\nCurrently, deep brain stimulation is used to control the tremors associated with Parkinson's, symptoms of obsessive-compulsive disorder and some other psychiatric conditions, including depression.\n\"Critically, it was the stimulation at the gateway into the hippocampus, and not the hippocampus itself, that proved effective,\" senior study author Dr. Itzhak Fried, a professor of neurosurgery at the David Geffen School of Medicine at UCLA, said in a university news release.\nSo it's difficult to generalize this study's results to other diseases that affect memory, she said, and the research didn't show if effects of temporary deep brain stimulation last beyond the study period.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This line of research is so preliminary that we won\u2019t criticize a story for omitting cost estimates. However, as the story notes, similar technology is used to treat some people with Parkinson\u2019s disease and other disorders, so the story could have told readers how much those applications cost.", "answer": 2}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions the cost of the device.", "answer": 1}, {"article": "At the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn.\n\"This drug has minor effects on normal cells other than neutrophils (white blood cells),\" said the study's senior author, Peter J. O'Dwyer, MD, a professor of Hematology/Oncology at Penn and director of the Developmental Therapeutics Program at the ACC.\n\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nIn both breast and other cancer trials, palbociclib has been shown to be safe with once-daily dosing, and its main adverse effect is reversible neutropenia, an abnormally low count of neutrophils, a type of white blood cell that helps fight infections.\nIn addition to inhibiting the cell cycle, palbociclib has been shown, for example to alter several recently described non-cell cycle functions of CDK4/6, a finding expected to expand its therapeutic role, O'Dwyer added.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release goes to some lengths in describing the quantitative and qualitative benefits of pairing palbociclib with other anti-cancer drugs, but offers not a word about costs. In this case, costs are significant. Pfizer has pegged palbociclib at $9,850 per month. Carrying an informal calculation forward puts the cost of the drug at about $40,000 per prolongation of survival for four months. The consequences of such pricing remain unclear owing to subsidies and discounts. But for many patients the costs are not covered by insurance and drugs may not be\u00a0accessible to all who need them. They also put a major strain on the entire health care system.", "answer": 0}, {"article": "Many migraines can be prevented by taking medication every day.\nMost people with migraine have attacks that happen repeatedly.\u201d\n\nPeople whose migraines are infrequent or mild may not be able to prevent them with drugs, the guidelines say.\nThese medications \u201care effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity,\u201d Silberstein and colleagues wrote in the new guidelines, which were based on a review of 284 publications.\nIn a summary of the guidelines written for patients and their families, this is how migraines are described:\n\nPreventive treatment involves taking a seizure drug and a beta-blocker every day to reduce the frequency, severity and duration of migraines.\nThe authors also noted that frovatriptan (Frova), which is used to treat migraine symptoms, can also help prevent menstrual migraines.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of migraine prevention drugs was not mentioned and cost is an important consideration.\u00a0 The costs range from pennies a day for beta blockers to over $300 for a monthly regimen of Trova. Even the guideline authors mentioned cost as a potential barrier.\n\u00a0", "answer": 0}, {"article": "Ilaris can lower the immune system\u2019s ability to fight infections.\n\u201cFor the first time, patients with TRAPS and HIDS/MKD, two painful and life altering diseases, have access to a treatment that may help improve their quality of life,\u201d said Badrul Chowdhury, M.D., Ph.D, director of the Division of Pulmonary, Allergy and Rheumatology Products in FDA\u2019s Center for Drug Evaluation and Research.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients:\n\nAll three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain.\nThe agency is also responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "FDA releases don\u2019t typically assess cost, but seeing as this treatment is already on the market, it would not have been much of an effort to include that information in the news release. One might assume that the costs of treating these rare diseases are substantial but the release gives no indication on cost, or whether the drug might be covered by insurance.\nAccording to one trusted source on average retail drug prices, llaris prescriptions cannot be filled at a typical pharmacy. Instead, the medicine is administered and distributed at a hospital or clinic. This suggests the drug may be very expensive.", "answer": 2}, {"article": "''This is a simple test that has high accuracy and can be run from a single drop of blood,\" says Robert Nagele, PhD, a professor of medicine at the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.\nThe only definitive way to diagnose the disease is by direct examination of brain tissue after the patient dies.\nThey are all in the very preliminary, very early stages.\nIt works by determining the amount of amyloid plaque, associated with the disease, in people's brains.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story includes a tentative estimate of what this sort of blood test might cost if it is approved.", "answer": 1}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\nThe story says the cost is roughly $30,000 to $50,000.\n", "answer": 1}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nIn anyone with 200 or more repeats, the body shuts off the gene.\nSince genes are used to make proteins, this genetic silencing means the encoded protein is never made.\nWith each subsequent generation, the number of repeats tends to rise.\nFor ethical reasons, Novartis tested the drug only in adults.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since the drug is in such an early stage of development,\u00a0we\u2019ll call this one not applicable.", "answer": 2}, {"article": "The positive results surprised even Stagl.\n\u201cWhile I certainly wouldn\u2019t say that anyone could take a 10-week course and be set for life, I think anyone could take a 10-week course and be much better at coping with stress.\u201d\n\nNext, the study team, led by Michael Antoni of the University of Miami, hopes to show that an easier-to-manage five-week group class works as well as the 10-week one.\nThe women who took the 10-week stress-management class shortly after surgery reported feeling better and having fewer depressive symptoms such as anxiety than those who took a one-day, breast-cancer education session.\n\u201cThis is really a teachable moment.\u201d\n\nThe skills taught in the course are useful at many stressful moments, Porter said, not just when cancer is diagnosed.\nIf a woman\u2019s stress level remains high indefinitely after diagnosis, she may have a worse outcome than if she can bring it back down, Stagl said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address costs at all. It is not clear whether the type of group-based\u00a0cognitive-behavioral stress management program\u00a0discussed in the study is free for most patients, whether it is likely to be covered by insurance, or whether it would require a significant out-of-pocket expense for breast cancer patients.", "answer": 0}, {"article": "\"As the kids with cystic fibrosis are living longer and longer, a lot of these ancillary problems are become more apparent,\" said C. Michael White, director of the Evidence-based Practice Center and lead author of the study.\nIn the 1950s, children with cystic fibrosis generally died before age 8.\nThe disease also affects the pancreas, making it difficult for the body to absorb food, which significantly stunts growth and often leads to early deaths.\n\"I could see that, for a lot of kids, the injections would become just part of the daily routine,\" he said.\nIn the cases studied, the researchers found that human growth hormone added 1.25 inches in height and three pounds to the patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention that human growth hormone is expensive; however, it would have been preferable if it reported an\u00a0actual dollar amount, as this information is readily available. \u00a0", "answer": 1}, {"article": "Cardinal says older adults need to realize that exercise can greatly improve their quality of life by maximizing function as long as possible.\n(Canes were OK.)\n\nHalf of the participants got a health education program involving regular in-person sessions and some stretching exercises, while the other group was told to aim for 150 minutes of aerobic activity as well as strength, flexibility and balance training both at the study's facilities and at home.\n\"Walking was the cornerstone of the program,\" says Thomas Gill, a professor of geriatrics at the Yale School of Medicine and an author of the study, which appears in Annals of Internal Medicine.\nThe exercise program pretty closely followed the government's recommendations for all adults, including older ones: 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity exercise per week, plus two strength sessions that hit all the major muscle groups.\nThe authors called on medical schools to \"start preparing students to prescribe exercise as effectively as they prescribe statins, and for health systems to support physicians in addressing inactivity just as they provide support in addressing other health risks.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rate this\u00a0category as non-applicable since the thrust of the story and the project it reports about is for elderly persons to adopt a routine of physical activity, the core of which is walking, which costs nothing. Certainly some costs are possible, say if for example a gym membership was desired, but neither the study or the story recommended that.\u00a0 Simple walking seemed to net ample positive results.", "answer": 2}, {"article": "In 2008, Gao struck out on his own, taking a job as director of a brand-new gene therapy center at UMass.\n\u201cWe are probably in the greatest innovative period of understanding human disease and how to make cures ever.\u201d\n\nThe concept of gene therapy is straightforward, beautiful even: Fix an illness caused by a faulty gene by replacing or supplementing a healthy new copy of the gene.\nFor the next 13 years, Gao would work for Wilson, engineering new and better viruses for the therapies, called \u201cviral vectors.\u201d These molecular FedEx trucks can be loaded with healthy versions of genes and deliver them to the correct location in the body.\nAdditionally, the brain is a closed compartment, so the risks of gene therapy are minimized\u2014other parts of the body, the liver or the lungs, say, are undisturbed.\nThe most promising candidate was adeno-associated virus (AAV)\u2014a virus that grows in the presence of adenovirus but is a completely different type.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While some therapeutic strategies appear to have been approved in China and Europe, according to the story, none has\u00a0been approved in the Unites States, suggesting that cost information isn\u2019t yet relevant. But the story does indicate how expensive these therapies might be, by\u00a0mentioning\u00a0a breathtaking bit of pricing by one European company: $1.4 million per injection.\nThis is enough to rate as Satisfactory, though the story could have done more to help patients\u00a0understand what pricing might look like for gene therapies, which is surely on the minds of the venture capitalists funding the research.", "answer": 1}, {"article": "His father\u2019s eventful medical history included a serious stroke and coronary bypass surgery.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\n\u201cDialysis may have prolonged his life, but I suspect only by a couple of months,\u201d Dr. Hladik said.\n\u201cHe said, \u2018I don\u2019t want to spend my time doing this,\u2019 \u201d recalled his son, Dr. Gerald A. Hladik.\nSo after considerable discussion, Mr. Hladik decided to skip the three weekly trips to a renal center, along with the resulting fatigue and dietary and travel restrictions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article could have included some quick facts about the cost of dialysis, as well as the costs of transportation, hospital time and nursing costs that are all involved in being treated as an out-patient at a renal clinic. There was one reference to costs when the story says that, in terms of time, dialysis treatment was \u201cthe equivalent of holding down a part-time job.\u201d", "answer": 0}, {"article": "The restrictive diet lasted for five weeks.\n\"Since none of the children stayed on the diet beyond five weeks, it is hard to know if this dietary intervention offers sustained benefit,\" he said, adding, \"Since it is more difficult to enforce restricted diets in older children, this approach may not be suitable for the majority of older children with ADHD.\"\n\"We think that dietary intervention should be considered in all children with ADHD, provided parents are willing to follow a diagnostic restricted elimination diet for a five-week period, and provided expert supervision is available,\" they concluded.\n\"If parents have noticed that a child's behavior seems to get worse with certain foods, it may be worth considering,\" said Ghuman, who is an associate professor of psychiatry and pediatrics at the University of Arizona in Tucson.\n\"But, for this diet to work, you have to be very consistent with it, and you have to pay attention to nutrition.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Neither story mentions specific costs. Both stories say that if parents are to embark on this diet, they will need to have their kids monitored. This story says that parents should have their children monitored by \u00a0\u201ca primary care doctor and, if possible, a dietician.\u201d That would make this diet extremely expensive and would require significant out-of-pocket spending given that insurance companies are not currently paying parents to see their doctor for ADHD-related diet monitoring.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nSteroids improve survival and reduce the chances of certain birth defects for extremely premature infants, even if the treatment course is not finished before delivery, according to a study funded by the National Institutes of Health (NIH).\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nAbout the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): The NICHD sponsors research on development, before and after birth; maternal, child, and family health; reproductive biology and population issues; and medical rehabilitation.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The two antenatal steroids (ANS) used in this study included betamethasone and dexamethasone, but their costs were never mentioned.\nA complete course of ANS was defined as 2 intramuscular doses of betamethasone administered 24 hours apart or 4 doses of dexamethasone administered 12 hours apart. According to drugs.com, 500 mL of dexamethasone costs $23.94.\nOur online search didn\u2019t uncover any price estimates for liquid Betamethasone. Drugs.com only lists topical Betamethasone prices.\nWe always like to see a ballpark range of costs in news releases, so consumers can estimate their therapy costs. Since costs are not discussed in the news release, we give it a Not Satisfactory rating here.\nIt\u2019s worth noting here that the actual costs of the steroids pale in comparison to the cost of the overall treatment of these infants. \u00a0If the partial treatment is even\u00a0partially effective, that could lower future medical care costs.", "answer": 0}, {"article": "For more information about the School of Medicine, see http://www.\n\"In addition to providing a new treatment option for patients with treatment-resistant, moderate to severe COPD, the new results also are important because they identify a potential biomarker for the disease and demonstrate that eosinophilic inflammation plays a role in flare-ups in COPD,\" Sciurba said.\n\"The goal of precision medicine is to give the right treatment to the right patient,\" said lead author Frank Sciurba, M.D., director of the Center for COPD and Emphysema and UPMC Pulmonary Function Exercise Physiology Laboratory, and visiting professor in the Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine.\nSimilar to METREX, the exacerbation rate was reduced by 20 percent in the high eosinophil group after 100 milligrams of mepolizumab.\nThe new study reports the results from two Phase III clinical trials evaluating the efficacy of mepolizumab, an antibody treatment that reduces the number of eosinophils in the blood, in moderate to severe treatment-resistant eosinophilic COPD by blocking the pro-inflammatory effects of interleukin-5.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs of the drug mepolizumab in the news release. An online search reveals that the price for the drug can run from $2,800 to $4,200 per vial (a one month\u2019s supply). Given that the drug appears effective only with some COPD patients, and its considerable price, readers would benefit from having this information, as well as perhaps the costs of standard therapies for COPD (triple inhalers and corticosteroids) which might still be needed by these patients.", "answer": 0}, {"article": "\u201cThis [medication] could really be transformative,\u201d said Hugh Taylor, an OB-GYN at Yale Medical School who led the key trials testing the drug.\nBut doctors have also found that the rate of retrograde menstruation is about the same in women with and without endometriosis, so they think additional factors spur the disorder in some.\nDoctors aren\u2019t sure why some women get it\n\nAdding to the mystery around endometriosis: No one knows exactly what causes it, but doctors have some theories.\nMood swings and night sweats were less common, and one woman in the trial died by suicide (though there\u2019s no indication that the medicine was a cause of her death).\n\u2022 Environmental factors: There\u2019s some evidence to suggest environmental exposures to certain chemicals may contribute to one\u2019s risk of developing endometriosis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job of describing the monthly cost ($850) for women who do not have health insurance. The inference is that insurers will cover the cost for others.", "answer": 1}, {"article": "For more information, please visit www.alzheimersprevention.org.\n\"We've been studying the impact of meditation on memory for more than 20 years, and are as encouraged as we've ever been on its powerful role in maximizing brain health,\" said Khalsa, president and medical director of the Alzheimer's Research and Prevention Foundation and a clinical associate professor of integrative medicine at the University of New Mexico School of Medicine.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\nThe article reviews decades of research into the impact that various meditation techniques have had on the prevention of Alzheimer's disease, focusing on one evidence-based practice that Khalsa says can be a powerful part of any Alzheimer's prevention and spiritual fitness program, Kirtan Kriya (KK), a meditation technique which has been successfully used to improve memory in studies of people with subjective cognitive decline and mild cognitive impairment.\nTUCSON, Ariz., July 15, 2015 /PRNewswire/ -- Meditation and spiritual fitness are key components in reducing the risk of Alzheimer's disease according to a new article, \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\", published in an early online version of the Journal of Alzheimer's Disease 48(1).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The Alzheimer\u2019s Research and Prevention Foundation states that the yoga technique is \u201caffordable\u201d in the news release. That\u2019s a step toward satisfying this criterion, but it\u2019s not clear whether the Foundation\u2019s definition of \u201caffordable\u201d is the same as readers\u2019 definition. Some numbers would have helped here. The Foundation\u2019s website provides instructions online on how to practice Kirtan Kriya yoga in six steps, and provides a link on how to order an accompanying CD for $20. Including a brief reference to that info in the release would have earned it a Satisfactory rating.", "answer": 0}, {"article": "By the time Harder saw a urologist, it had skyrocketed to 20.\nWhen I went back to my urologist, he said, \u2018Why spend money flying around the country when we can take care of you here?\u2019 I said, \u2018Because 85 percent is better than 40 percent.\u2019\u201d\n\nVCU Medical Center was one of the places Grandon had researched to get his diagnostic testing done, and a few phone calls later, he was on a plane flying across the country to see Yu.\n\u201cRight now, I think probably 50 or 60 percent get imaging.\u201d Sometimes, these are patients pushing their doctors for a referral as one of Yu\u2019s patients did last year.\nHe ends up diagnosed with cancer only after the tumor has spread to his bone or lymph nodes years later.\u201d\n\nMagnetic resonance imaging and targeted biopsy for the prostate have provided relief for patients like Harder who have not been able to get an accurate diagnosis.\nAfter Harder\u2019s third biopsy, his urologist was ready to throw in the towel, and that\u2019s when Harder was referred to Jinxing Yu, M.D., at VCU Health.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "MRIs cost significantly more than ultrasounds, but that fact isn\u2019t mentioned. According to a story in the Wall Street Journal, an MRI can cost from $600 to more than $2,000, although Medicare and many private insurers typically cover some or all of that cost. Cost is all the more significant if, as VCU\u2019s director of oncologic and prostate imaging speculates in the news release, MRIs are eventually used like mammograms, with men getting baseline MRIs followed by repeated periodic scans if warranted by bloodwork and family history.\nSome mention of cost, relative cost or cost-effectiveness was warranted.", "answer": 0}, {"article": "This research builds upon previous studies demonstrating that art, music, and other similar therapies can effectively reduce symptoms of dementia without medication.\nThe apps were freely available on iTunes and varied greatly in their cognitive complexity--from an app that displayed puppy photos to one that featured Sudoku puzzles.\n\"Tablet use as a nonpharmacologic intervention for agitation in older adults, including those with severe dementia, appears to be feasible, safe, and of potential utility,\" said Vahia.\nThe study also found that the tablets demonstrated significant effectiveness in reducing symptoms of agitation, particularly--but not exclusively--among patients with milder forms of dementia.\n\"We started showing him Romanian video clips on YouTube, and his behavior changed dramatically and instantaneously,\" said Vahia.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t mention the price of the computer tablet used. It does note that the apps used were free to download on iTunes.", "answer": 0}, {"article": "Van Hemelrijck and colleagues studied more than 30,000 men in Sweden with prostate cancer who got hormone therapy between 1997 and 2006, for about three years.\n\"This is not a colossal risk,\" Rippon said.\n\"It makes a lot of sense and could one day change treatment guidelines.\"\nMore than 670,000 men are diagnosed with prostate cancer globally every year, making it the second-most common cancer in men, after lung cancer.\nThey compared the rate of heart problems in those patients to the rate in the general Swedish population.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nCosts are not mentioned in the story.", "answer": 0}, {"article": "He was not involved in the new research.\n\"Five percent of the U.S. population will be diagnosed with colon cancer within their lifetimes,\" said Dr. Arun Swaminath, director of the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\nTUESDAY, Aug. 11, 2015 (HealthDay News) -- Colonoscopy can save lives, but experts agree that testing rates remain too low.\nThe study found that patients classified under the scoring system as low-risk did, in fact, have far fewer advanced abnormal growths that might develop into cancer, compared to patients classified as high-risk.\nThe system might also make colon cancer screening more efficient and boost the number of people who get checked for the disease, said a team led by Dr. Thomas Imperiale of Indiana University Medical Center, in Indianapolis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The question of cost is cited in the final line of the story, which suggests that the scoring system can \u201caddress escalating health care cost issues.\u201d But we didn\u2019t think that was specific enough to warrant a Satisfactory score. The story doesn\u2019t clue readers in to the fact that the financial burden can be measured in billions of dollars \u2014 a single screening test recommended for millions of Americans can cost thousands of dollars apiece. The other cost issue specific to this test is that it takes valuable time for providers to retrieve a reputable risk calculator when sitting with a patient and enter in the specific data points, including in this case waist circumference, which clinicians often do not measure as a \u2018vital sign\u2019 per se.", "answer": 0}, {"article": "Medication is often the first line therapy but relief can be inadequate and temporary.\nThe most common adverse events reported during the study included pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate, and the inability to control urine because of an urgent need to urinate.\nWhile current surgical options, such as the 'gold standard' surgery, Transurethral Resection of the Prostate (TURP), can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).\nPerformed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\nThe Northwestern Medicine Urology Program ranks amongst the nation's most experienced and well respected, providing comprehensive inpatient and outpatient care, including state-of-the-art diagnostic and treatment capabilities for men, women and adolescents.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the costs of the procedure or the patented system used, nor of the downstream costs associated with recovery from the procedure. There was also no data on how long patients were followed and how many required a repeat intervention\u2013either repeat UroLift or other invasive treatment. This outcome has implications for both costs and effectiveness.", "answer": 0}, {"article": "Based on the overall results, Devinsky believes CBD should be evaluated for epilepsy types beyond Dravet syndrome, which is caused by a genetic mutation and affects about one in 20,000 to 40,000 children in the United States.\nConsidered a spectrum disorder, different epilepsy syndromes are defined by clusters of symptoms or features and treated accordingly.\nShe was not involved in the new study.\nAn interested party, such as a drug company, may also petition for the process to begin.\nHowever, there was a downside.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was not a discussion of costs for this intervention\u2013this was the weak spot in the story.", "answer": 0}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nIf the experimental test pans out, \"a pediatrician could collect saliva with a swab, send it off to the lab and then be able to call the family the next day,\" says Steven Hicks, an assistant professor of pediatrics at Penn State Hershey.\nAnd microRNAs offer a promising way to assess concussions in adults as well as children, says Bhomia, whose research involves a range of \"biomarkers\" for traumatic brain injury.\nBut up to 25 percent of young patients \"go on to have these prolonged headaches, fatigue, nausea, and those symptoms can last sometimes one to four months,\" Hicks says.\n\"When they came to our medical center and received the diagnosis of concussion, we evaluated them with some standard survey-based tools and then we also got a sample of their saliva,\" Hicks says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this research is in early stages and it could be argued that it is too early to insist on a discussion of cost, the eventual price of this test will determine whether it would be used widely or not. For example, if it cost only a few dollars, it might be widely used by pediatricians (assuming it really works), but if it cost hundreds of dollars, it might not be used. The story should have at least tried to include some sort of ballpark cost estimate in order to tell the audience whether this sort of test would be practical.", "answer": 0}, {"article": "But two days later, most patients were satisfied.\n\"Emergency nurses and doctors need a variety of pain-relieving options when treating patients, given the concerns around opioids such as morphine, which carry the risk of addiction when used long-term,\" Cohen said in a university news release.\nOverall, nearly 83 percent of acupuncture-only patients said they would probably or definitely repeat their treatment, compared with about 81 percent in the combined group, and 78 percent who took painkillers alone.\nMONDAY, June 19, 2017 (HealthDay News) -- Acupuncture is a safe and effective alternative to pain medications for some emergency room patients, a new study reports.\nThe study -- billed as the world's largest randomized, controlled trial of acupuncture in the emergency department -- included 528 patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the cost of acupuncture treatments in the story, nor was there any comparison between such costs and the costs for standard analgesic drugs that might be administered in an emergency department.\nA provider trained in acupuncture would need to be available at the time the patient needed assistance. If acupuncture increased time in the ED, that would add cost and reduce capacity for other patients. These are important considerations (as cost drivers) in a fast-paced environment.", "answer": 0}, {"article": "Kris-Etherton and colleagues did an intensive study with 45 typical Americans \u2013 all overweight or obese, but with healthy cholesterol and blood pressure levels.\n\u201cI love guacamole and with my recipe, I'll use avocados, cilantro, lime juice and garlic... and then sometimes I'll put salsa in, or red pepper flakes.\u201d\n\nBut like anything, too much of a good thing can be harmful.\nSaturated fat \u2013 the kind found in meat and butter \u2013 has a different chemical structure from the unsaturated fats found in plant products.\nIt\u2019s tough to test diets in real life, because people eat so many different things, but the team controlled what everyone ate, feeding them carefully calibrated diets.\nThe two moderate-fat diets looked a lot like the average American diet, with about a third of calories coming from fat.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address costs. An avocado a day might add up to $30 or more per month, so that\u2019s not irrelevant. Competing stories gave pricing information or at least noted that avocados can be expensive.", "answer": 0}, {"article": "Lee believes ibuprofen strips could be useful for sports participants, helping alleviate conditions such as tendonitis, and repetitive strain injuries.\nWe\u2019ve tested them in our polymers with very good results, we\u2019ve been able to get increased loadings of drugs in the polymer and we\u2019ve shown almost across the board that we can get a steady release rate of that drug from the polymer as well.\u201d\n\nThe team says TEPI patches could go on sale within three years, and Medherant is working with some large, unnamed, pharmaceutical companies to get them ready for market.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\nAccording to Andrew Lee, co-founder of Medherant, \u201cwe\u2019ve only been in the lab about 12 months, but in the 12 months we\u2019ve essentially assessed about 90 percent of the drugs that are currently available as either creams or patches.\nAn ibuprofen patch that delivers the painkiller directly through the skin to the site of pain, at a consistent dose for up to 24 hours, has been developed by UK researchers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rate this\u00a0N/A since the patches are still in development for the consumer market. Having said that, we should point out that generic ibuprofen is very inexpensive. \u00a0It is very likely that the TEPI system will cost the consumer much more.", "answer": 2}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Any story about a screening test should not only include the cost of the test (which this story did not), but more importantly, the costs of preventive care.\u00a0 In this case, the use of a statin drug simply based on a rather controversial laboratory test", "answer": 0}, {"article": "Pill That Hits A Cause Of Cystic Fibrosis Beats Expectations\n\nMore than 20 years after the gene behind cystic fibrosis was identified, a pill that could fix the problem in some people is getting closer to reality.\n\"It is larger than any other clinical intervention we've ever had in cystic fibrosis.\"\nThe improvement at six months was still present almost a year after the study's start.\nBut a key takeaway is that the medicine gets at a root cause of cystic fibrosis in some people rather than just relieving their symptoms.\nNow there are some promising results from a study in 161 people with a specific genetic mutation that affects about four percent of cystic fibrosis patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "More explicitly than some other stories we saw, this blog included an estimate that the drug \u201cwould command a very high price, perhaps $250,000 a year.\u201d", "answer": 1}, {"article": "\"We found that the combination of two anticytokines containing extra-low doses of antibodies against TNF\u03b1 and IFN?\nFlorence, Italy - 9 July 2016: Immunotherapy reduces cardiovascular risk in patients with rheumatoid arthritis, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2016 by Professor Aida Babaeva, head of the Department of Internal Medicine, Volgograd State Medical University, Volgograd, Russia.1 The combination of two extra-low dose anticytokine drugs reduced rheumatoid arthritis disease activity and cardiovascular events.\nFor example, rheumatoid arthritis is associated with dysfunction of the blood vessel lining (called endothelium), which leads to lipid accumulation in the artery wall, plaque formation and atherosclerosis.\nThe incidence of cardiovascular events (unstable angina, severe hypertensive crisis, and deterioration of chronic heart failure) was more than double in the group on conventional disease-modifying drugs alone (37%) compared to those also taking the combination of anticytokines (13%).\nIn patients with highly active disease, the standard biologics are better at preventing severe complications such as progressive joint destruction and/or systemic manifestations (vasculitis, uveitis, involvement of internal organs).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention of costs, whatsoever. This may be a lost learning opportunity because these drugs are not only very expensive, but are also at the ends of their patent lives and hence generic companies are making cheaper biosimilars.", "answer": 0}, {"article": "WASHINGTON (Reuters) - A new, longer-lasting \u201cmorning-after\u201d pill to prevent unwanted pregnancy appears to work with no unexpected side effects, U.S. health regulatory staff said in documents released on Tuesday.\n\u201cThere is no doubt that ulipristal acts an abortifacient because the drug blocks progesterone receptors at three critical areas,\u201d an action that \u201cinterferes with the hormone action of progesterone to prepare the endometrium for implantation and to support the early pregnancy,\u201d the group wrote.\nWomen\u2019s health advocates have welcomed the potential for another contraceptive option, but some critics contend the drug is more akin to the abortion pill, sold by Danco Laboratories as Mifeprex and also known as RU-486 or mifepristone.\nOn Thursday, the FDA\u2019s advisers will weigh HRA Pharma\u2019s data and offer recommendations before the agency later makes its approval decision.\nFor ella, \u201cwhile you\u2019re going to have to go and get a prescription for it, it gives you a little bit more leeway in terms of putting your ability to put your life on hold and get this healthcare need taken care of,\u201d said Amy Allina, program and policy director for the National Women\u2019s Health Network.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs. Although it is hard to say definitively how much the drug would cost in the US since it is not yet available, the story could have mentioned the cost of the drug in Europe or provide an estimate from the drug manufacturer or even from an analyst.", "answer": 0}, {"article": "Just one center in the north of the country offers proton therapy for certain types of eye tumors.\nWhile the proton therapy market is expected to more than double by 2018, with an estimated 300 proton therapy rooms, Jongen's Brussels-based company IBA is working on a smaller and cheaper model they hope will make proton therapy more accessible.\n\"I have a number of letters from parents of young kids saying if it had not been for this treatment we would have lost our kid,\" he said.\nHealth practitioners have been searching for a magic bullet that goes straight to the source of the cancer -- and everything from monoclonal antibodies, which carry cancer drugs direct to cancer cells, to straight surgery to cut out tumors have been used with varying degrees of success.\n\"I started to designing equipment (for) proton therapy of cancer -- that was a radically new idea,\" Jongen told CNN.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention the cost of building a proton beam treatment center ($125 Million) but it does not speak to the real issue of the costs of treatment directly. Medicare reimbursement for proton beam treatment of prostate cancer is about $32,000, whereas IMRT is reimbursed at about half that amount.", "answer": 0}, {"article": "Still, the authors say the study strengthens the growing body of evidence that spicy food may have protective health properties that can lead to a longer life.\nParticipants were followed for an average of 18.9 years.\nThe research is observational, so no cause and effect relationship can be established.\nThe authors suggest further research should investigate the benefits of other spices and the effects of certain chili pepper subtypes.\nLike spicy foods?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. The intervention was an easily available and inexpensive food.", "answer": 2}, {"article": "In traditional transplants, hair follicles are taken from an area that runs an inch or two above the ears and temples to the back of the head.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\nIf you take that hair and use it in the hairline, it can end up looking harsh and pluggy, because the hair is too thick.\u201d\n\nDr. Umar was inspired to develop the procedure in part from personal experience.\nThe other patient, a 29-year-old man who had also undergone a traditional transplant, was likewise \u201cunhappy about his hairline, which he felt was too harsh and straight,\u201d Dr. Umar wrote.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The closest readers are given about any sense of costs is the amount of work involved. The story says \u201cOn average, a procedure involves 1,500 to 1,800 follicles and takes about eight hours, with breaks.\u201d Cosmetic surgeons don\u2019t work cheaply, and insurance is likely not to cover these procedures. All it would have required is one question to the surgeon, \u201cHow much does it cost to transplant 1,500 to 1,800 follicles\u201d?\n\u00a0", "answer": 0}, {"article": "[1] A troponin test measures the level of troponin proteins in the blood.\n\"[2]\n\nWriting in a linked Comment, Louise Cullen and William Parsonage from the Royal Brisbane and Women's Hospital, Queensland, Australia, and Martin Than from Christchurch Hospital, New Zealand, say, \"The ultimate validation for the safety and efficacy of discharging patients with cardiac troponin concentrations less than 5 ng/L will be the report of clinical outcomes after this threshold is implemented in routine clinical practice...Finally, what further assessment, if any, is needed for those patients identified as low risk and suitable for early discharge?\nDr Shah and colleagues prospectively evaluated the negative predictive value (the probability that patients were not at risk) of heart attack or subsequent death from a heart condition after 30 days for a range of troponin concentrations.\n\"We have identified a cardiac troponin concentration (less than 5 nanograms per deciliter; <5 ng/L) below which patients are at very low risk of heart attack either during the admission or in the ensuing 30 days.\nThe researchers found that a troponin threshold of <5 ng/L at presentation identified around two-thirds (61%) of patients at very low risk of heart attack and may have been eligible for early, safe discharge--with a high negative predictive value of 99.6%.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes repeated reference to claims by the study\u2019s authors of substantial savings to the health care system, but no quantitative data are included. More significantly, there is no information presented about the cost of the high-sensitivity test or comparison to current per-patient cost for evaluating acute coronary syndrome in the British health care system. At a minimum, one would want to know the cost of this new test compared to standard troponin tests. Further work would be needed to assess the relative downstream costs associated with this new test.", "answer": 0}, {"article": "They called for more studies to help understand all the factors that contribute to sex and gender differences in smoking.\n\"This result emphasizes the need for gender-specific programs to quit smoking, as well as taking into consideration a menstrual cycle phase during addiction treatment in women,\" the researchers conclude.\n\"One of the factors contributing to these differences may be that women crave cigarettes more than men and that their desire to smoke is influenced by hormonal fluctuations across the menstrual cycle.\"\n\"While overall more men than women smoke cigarettes, women and girls take less time to become dependent after initial use and have more difficulties quitting the habit,\" the researchers write in their study.\nAccording to small study conducted by researchers at the University of Montreal, women are more likely to crave cigarettes and have trouble quitting when in the follicular phase of their monthly cycle.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since the story let the researchers get away with saying, \u201cThis result emphasizes the need for gender-specific programs to quit smoking\u2026\u201d, we might have dinged it for not projecting what the costs of such programs might be. \u00a0But we\u2019re going to rule this Not Applicable because it would be difficult at this point to think about all that might be involved in costs of such an approach, even if this research was close to true real-world application, which it is not.", "answer": 2}, {"article": "Science took the unusual step of allowing the scientists to speak to the media before publication.\nThe time from gene discovery to successful drug may be shortening, but there are only a handful of successful drugs so far, and for a while at least, the appearance of new ones will be slow.\nAs a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\nThe only way to fix that would be gene therapy, where a healthy form of the gene would supplant the damaged one.\n\"But it wasn't until 20 years later that we were able to find drugs that directly target the underlying cause of cystic fibrosis,\" says Fred Van Goor, who led the team at what is now Vertex Pharmaceuticals that developed Kalydeco.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It doesn\u2019t come until the last sentence in the story, but it also leaves listeners and readers with a pretty sobering reality: \u201cThe time from gene discovery to successful drug may be shortening, but there are only a handful of successful drugs so far, and for a while at least, the appearance of new ones will be slow.\u00a0They\u2019re also likely to be expensive. Kalydeco costs in the neighborhood of $300,000 per year.\u201d", "answer": 1}, {"article": "While the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\nWhereas in Parkinson's disease and essential tremor, the target for the electrodes are nodes within the motor circuits, the Alzheimer's study targeted the fornix, which is part of the memory pathway.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\nInitial research took place between 2012 and 2014 at six hospitals throughout the U.S., including Banner Alzheimer's Institute in Phoenix and Banner Sun Health Research Institute in Sun City, as well as one institution in Canada.\nAdverse effects such as headache and infection occurred in 11.9% (5 of 42) of the patients in this study, consistent with rates reported in other DBS trials.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of this procedure or the maintenance costs of the device. These numbers should be well-known as the device is currently used in Parkinson\u2019s patients and others. An article published in WebMD in 2011 estimated the surgery runs between $30,000 and $50,000.", "answer": 0}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that \"The cost of RapidArc is similar to other radiation therapies. \u00a0It is covered by Medicare and most insurers\". But that doesn\u2019t tell us the cost, and it seems to suggest that since it is covered by insurers, the consumer need not worry about the costs. \u00a0In fact, the acquisition of this sort of equipment is quite expensive and the doctors investing in the technology will need to recover their costs, which may lead to unnecessary treatments.\u00a0 That\u2019s why actual cost is a big deal and should have been in the story. ", "answer": 0}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs of the \"paint\" nor of the equipment needed to visualize where the \"painted\" cells are localized.\nFrom the website of the company that made the imaging equipement, it was not apparent that an apparatus was even available that would accomodate a \"patient\" larger than a rodent.", "answer": 0}, {"article": "June 7, 2012 -- Drinking three cups of coffee per day may help turn the tide against Alzheimer's disease among older adults who are already showing signs of memory problems, a new study shows.\nThis is equivalent to drinking several cups of coffee a few hours before giving blood.\nAlzheimer's disease is the most common type of dementia.\nThe findings will appear in the Journal of Alzheimer's Disease.\nCoffee was the main, or only source, of caffeine among people in the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of coffee is not in question.", "answer": 2}, {"article": "At 6 months, casting resulted in measures of ankle function equivalent to that with surgery.\nAmong older adults with an unstable ankle fracture, the use of a modified casting technique known as close contact casting (a molded below-knee cast with minimal padding) resulted in similar functional outcomes at 6 months compared with surgery, and with fewer wound complications and reduced intervention costs, according to a study appearing in the October 11 issue of JAMA.\n\"Close contact casting was delivered successfully for most participants, substantially reducing the number of patients requiring invasive surgical procedures at the outset and additional operations during a 6-month period,\" the authors write.\nKeith Willett, M.B.B.S., F.R.C.S., of the University of Oxford, United Kingdom, and colleagues randomly assigned 620 adults older than 60 years with acute, unstable ankle fracture to surgery (n = 309) or casting (n = 311).\nA modified casting technique has been developed, close contact casting, which uses minimal padding compared with traditional casting and achieves fracture reduction by distributing contact pressure by close anatomic fit.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes that casting instead of surgery as an initial treatment would result in \u201creduced intervention costs\u201d but that\u2019s not very helpful if you\u2019re unsure of the base cost of surgery.\nEstimates of a cost differential would have been helpful. Close contact casting would be much cheaper than open surgery for these fractures.", "answer": 0}, {"article": "Newly postmenopausal women who received estrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer\u2019s disease, a Mayo Clinic study published this month in the Journal of Alzheimer\u2019s Disease found.\nA rapid decline in estrogen with menopause may be associated with an increased risk of Alzheimer\u2019s disease risk in women.\nResearchers investigated the brain amyloid deposition in 68 women ages 42 to 59 who participated in the Kronos trial during this critical window.\nOf the 68 women, 21 received estrogen via a skin patch, 17 received estrogen orally and 30 received a placebo.\nThe oral treatment was not associated with lower amyloid deposition.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs for hormone therapy are readily available but they are not broached in this release.", "answer": 0}, {"article": "More than half of those women who had been categorized as mastectomy-only patients were also able to go the lumpectomy route and experience a good outcome.\nThe women were classified into three groups as the study began: \"marginal\", meaning that the women were eligible for a lumpectomy to conserve the breast, but that it would be disfiguring or require several operations; \"mastectomy-only\", meaning a lumpectomy was not considered possible; and \"inoperable\", meaning that doctors believed that even a mastectomy would not completely remove the cancer.\nAfter the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.\nThe most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.\nThe investigation was funded by the American College of Surgeons Oncology Group and led by Dr. Julie A. Margenthaler, an assistant professor of surgery and a breast surgeon at the Siteman Cancer Center at Washington University in St. Louis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs in this story. It could have pointed out that two of the estrogen-lowering drugs tested in this study are off patent and relatively cheap, whereas the third drug, exemestane,\u00a0is a brand name drug that remains quite costly.", "answer": 0}, {"article": "(Reuters) - Merck & Co\u2019s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\nKeytruda, among a class of medicines called PD-1 inhibitors, is Merck\u2019s top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer.\nPD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not mentioned and that\u2019s a big omission when you\u2019re discussing Keytruda. Drugs in this class of checkpoint inhibitors are estimated to cost about $150,000 a year.", "answer": 0}, {"article": "Politi said a serving of walnuts is about 14 halves, which adds up to 180 calories.\n\"Given walnuts are a high-energy food, a prevailing concern has been that their long-term consumption might be associated with weight gain,\" said study author Dr. Emilio Ros, director of the Lipid Clinic, Endocrinology & Nutrition Service at the Hospital Clinic of Barcelona, in a press statement.\nAfter one year, both groups experienced minimal body weight, triglyceride, and HDL cholesterol changes, but the walnut-eaters had significant reductions in LDL cholesterol (\"bad\" cholesterol) compared to the nut-free control group.\nThe research shows the well-known cholesterol-lowering effect of eating walnuts works equally well in the elderly, even in the long term, the authors reported at the Experimental Biology conference in San Diego.\nWalnuts are especially heart healthy because they have more polyunsaturated fat than almonds, cashews, peanuts, pecans, pistachios, and macadamia nuts per serving.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this is a study of older adults\u2013who are often on fixed incomes\u2013an estimate of cost would have made the story stronger. But because walnuts aren\u2019t notably expensive compared to other nuts, we\u2019ll give this a pass.", "answer": 2}, {"article": "(That\u2019s a high dose; a 3 oz.\nWhat\u2019s more, the people who showed the highest blood levels of the omega-3 fats (people absorb it at different rates) showed the greatest reduction in scarring \u2014 13% \u2014 compared to those with the lowest levels.\n\u201cThe omega-3 fatty acids seem to be preventing scarring of the otherwise healthy muscle that now has to overwork because of the heart attack,\u201d says Kwong.\nFor the study, published in the journal , they studied nearly 360 people who recently had a heart attack, who were randomly assigned to take 4g of omega-3 fatty acids or a placebo pill for six months.\nThe remaining healthy tissue starts to compensate for the compromised tissue, but has to work harder to maintain the heart\u2019s normal pumping function.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of the intervention are not disclosed. A casual reading of the news article may lead one to believe that over-the-counter fish oil was used in the treatment arm of the study. However, our\u00a0own careful reading of the original study reveals that GlaxoSmithKline (Research Triangle Park, NC) provided both the fish oil and placebo pills. (The study was solely funded by the\u00a0National Institutes of Health.)\nA curious reader might ask what is the cost discrepancy between the fish oil by GlaxoSmithKline and a standard over-the-counter fish oil product, too.", "answer": 0}, {"article": "(CNN) Finding ways to fight the flu just got a tad more ribbeting -- that is, if you ask some researchers who have turned their attention to frogs.\n\"I need to come up with a strategy to deliver it systemically as well; maybe an injectable, which goes in the bloodstream and kills influenza viruses,\" Jacob mused.\n\"We have identified a potentially new treatment for H1N1 human influenza virus, which is a peptide that comes from the skin of a frog from southern India,\" said Joshy Jacob , an associate professor in the Emory University School of Medicine's microbiology and immunology department, who led the study.\n\"Amphibians, especially certain groups of frogs, produce and store large amounts of antimicrobial peptides in specialized granular glands in the skin,\" said Louise Rollins-Smith, associate professor of pathology, microbiology, and immunology at Vanderbilt University School of Medicine.\n'It makes the virus particle fall apart'\n\nThe researchers observed how the peptides interacted with influenza viruses under a microscope and in mice.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story describes basic research that has not even reached the human clinical test stage. Because it makes this clear and adds lots of backstopping so as to prevent readers from wondering if this is an available treatment, we\u2019ll rate this N/A.", "answer": 2}, {"article": "For more information about our products and organization, visit http://www.\nFebruary 28, 2017 - For infants with congenital malformations of the ear, a treatment system called EarWell can gently reshape the ear--avoiding the pain and cost of later surgery, reports a study in the March issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nWhile the EarWell system is not new, the report is the largest study of congenital ear malformations treated with this approach--including a standardized approach to treatment and assessment of the results.\n\"While we can operate on ears later in the patient's life, waiting not only increases the surgery's difficulty and expense, but may expose the child to teasing, bullying, and loss of self-esteem,\" comments Editor-in-Chief Rod J. Rohrich, MD, in a featured video on the Plastic and Reconstructive Surgery website.\nThe official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery\u00ae brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues\n\nThe American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not address cost at all, which is particularly unusual given that the release focuses on the use of a product that is already on the market. Given that online cost estimates for the EarWell system range from $2,500 to $4,500 per ear, this is a significant oversight.", "answer": 0}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The prototype device is said to cost $1000.\u00a0 At this stage of development, the exact cost of the device and of screening is difficult to predict.\u00a0 We\u2019ll give the story the benefit of the doubt given the early stage of development of the device", "answer": 1}, {"article": "The procedure is not yet recommended by professional medical societies, said Dr. Sara Brubaker, a specialist in maternal and fetal medicine at N.Y.U.\n\u201cJust understanding that it\u2019s possible is exciting.\u201d\n\nBut it will take further studies following C-section babies for many years to know to what degree, if any, the method protects them from immune and metabolic problems, he said.\nBut the first to reach an infant born by cesarean section come mostly from the environment \u2014 particularly bacteria from inaccessible or less-scrubbed areas like lamps and walls, and skin cells from everyone else in the delivery room.\nThe small proof-of-principle study suggests a new way to inoculate babies, said Dr. Maria Gloria Dominguez-Bello, an associate professor of medicine at New York University and lead author of the report, published on Monday in Nature Medicine.\nThe results show the complexity of labor, said Dr. Alexander Khoruts, a microbial expert and associate professor of medicine at the University of Minnesota.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not discuss the costs associated with inoculation. However, it\u2019s implied that vaginal microbial transfer is very inexpensive (it only requires a piece of gauze, saline, and a sterile bottle \u2013 all standard hospital supplies) so we won\u2019t ding the story for this omission. With that being said, there is a tacit assumption in the article that the transfer of bacteria from the mother\u2019s vaginal fluids to the newborn is always in the best interest of the newborn. Clearly this is not the case as we will articulate later. If there is a risk of the transfer of less than desirable bacteria, it is reasonable to assume that bacterial screening of vaginal secretions might be undertaken (which would add cost). The transfer of pathogens to the newborn inducing infection would also have a cost. While it is beyond the scope of this report, we think that thinking about the potential downsides of a new intervention is in order.", "answer": 2}, {"article": "The U.S. Preventive Services Task Force (USPSTF) says there is no proof that the benefits of routine mammogram screening outweigh the risks for average-risk women in their 40s.\n\"Let's say 10,000 women in the world were going to die of breast cancer that developed in their 40s,\" Brawley tells WebMD.\n\"What we are seeing is that women with mammogram -detected breast cancer require less treatment,\" Malmgren tells WebMD.\nThe finding comes from a careful study of nearly 2,000 women diagnosed with first-time breast cancer at age 40 to 49.\nFeb. 22, 2012 -- When women in their 40s get breast cancer , their tumors need less intense treatment and recur less often if they were first detected during routine mammogram screening.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs of mammograms.\u00a0 Stories should not assume that all insurance companies will cover costs of mammograms for women in their 40s.\u00a0 Cost is an issue and can be addressed in just one additional line in a story.", "answer": 0}, {"article": "Liao said the robotic surgery was the right choice for Holmes, the bypass patient.\nThe learning curve for cardiac surgeons was too steep, though, and the system\u2019s tools weren\u2019t as useful for heart surgeries as they were for other procedures, said Dr. Goya Raikar, a cardiothoracic surgeon at Regions Hospital in St. Paul.\nThe number of da Vinci robots has doubled in Minnesota in less than two years, with two at the university and four at the Mayo Clinic in Rochester.\nThe da Vinci is criticized by health policy experts as the poster child for the medical arms race \u2014 the competitive fever among hospitals to buy new technology whether or not it improves care.\nUsing the da Vinci, Liao disconnected the mammary artery \u2014 which usually directs blood to the left breast \u2014 and connected it to the heart so normal blood flow could resume.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article says the daVinci devices have \"a million dollar price tag.\" But it does not say whether any of this cost is passed along to insurers and patients in the form of higher costs. \nThe story also mentions the possibility that hospital costs will be reduced but does not provide any data to back it up.\u00a0 \u00a0\nNonetheless, at least it nodded in the direction of costs. \u00a0", "answer": 1}, {"article": "As part of a longer term project funded by F. Hoffman-La Roche, the team previously tested a collection of approximately 550 potential tracer molecules and identified six promising tracers, eventually narrowing them down to three to be made and tested as candidate Tau PET radiopharmaceuticals.\nAn additional six older healthy controls were recruited for full-body scanning.\nThe third part of the study examined six older controls undergoing whole-body scanning.\nSusan Resnick and Madhav Thambisetty are employees of the NIH, National Institute on Aging.\nIt was published in the December 2018 issue of the journal.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t discussed.", "answer": 0}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the drug manufacturer speculates that sales will top $1 billion, the story gives no indication of what the cost is for the individual.\u00a0\u00a0\u00a0", "answer": 0}, {"article": "The earliest trials with patients who developed POCD were performed after the 1950s.\nThe good news, according to a Brazilian study published by the journal PLoS One, is that two relatively simple measures can help to reduce the incidence of POCD: administering a small dose of the anti-inflammatory drug dexamethasone immediately before an operation and avoiding profound anesthesia during the operation.\n\"The results reinforce recent evidence of the importance of avoiding deep anesthesia,\" Carmona said.\nIf so, the use of an anti-inflammatory drug may have a protective effect,\" said Maria Jos\u00e9 Carvalho Carmona, a professor of anesthesiology at the University of S\u00e3o Paulo's Medical School (FM-USP) and principal investigator for the study.\nThe researchers evaluated 140 patients aged between 60 and 87 who underwent surgery under propofol-induced general anesthesia at the Central Institute of Hospital das Cl\u00ednicas, FM-USP's teaching hospital, in most cases for removal of gallstones.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t discuss cost at all, which is somewhat surprising given that dexamethasone has been on the market for many years with various clinical applications. It\u2019s not that dexamethasone is especially expensive (it isn\u2019t \u2014 though the cost isn\u2019t necessarily negligible), but that cost needs to be addressed. Readers are simply given no information about cost.", "answer": 0}, {"article": "Cerebral palsy is a common yet understudied neurodevelopmental problem in the U.S.\nEach person's genome, or complete set of DNA, is like a word that's the length of 3 billion characters; but spelled with only the letters A, T, C or G. Traditional DNA sequencing techniques decode sections of DNA 700 characters at a time, while NGS takes advantage of parallel computing capabilities, enabling scientists to decode millions of DNA fragments.\nWhile the study findings indicate that there is a consistent signal present in circulating blood cells of children with spastic CP that remains from early childhood to the teenage years, the researchers say they need to further study samples from different age groups, including teenagers, toddlers, and infants from birth to 2 years.\nThe approach uses sophisticated machine learning techniques and algorithms to sort through hundreds of gigabytes of NGS data looking for these distinct DNA methylation patterns.\nThe work represents a collaboration among researchers at Nemours, the University of Delaware (UD) and Genome Profiling LLC (GenPro for short).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this proposed diagnostic approach anywhere in the release. The entire approach to the claims made in this release relies on next generation sequencing of blood samples which can run into hundreds and sometimes thousands of dollars. The research paper points out that the approach relies on the use of parallel computing facilities, a highly expensive capability for many medical centers.", "answer": 0}, {"article": "Drinking concentrated blueberry juice improves brain function in older people, according to research by the University of Exeter.\nThe research was carried out in association with the University of the West of England, and the concentrated blueberry juice (BlueberryActive) and some funding for the study was provided by CherryActive Ltd, which produces cherry, beetroot and blueberry products in concentrate and capsule form.\nThe new paper, \"Enhanced task-related brain activation and resting perfusion in healthy older adults after chronic blueberry supplementation\", is published in the journal Applied Physiology, Nutrition and Metabolism.\nOf the 26 healthy adults in the study, 12 were given concentrated blueberry juice - providing the equivalent of 230g of blueberries - once a day, while 14 received a placebo.\nDr Joanna Bowtell, head of Sport and Health Sciences at the University of Exeter, said: \"Our cognitive function tends to decline as we get older, but previous research has shown that cognitive function is better preserved in healthy older adults with a diet rich in plant-based foods.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this blueberry concentrate. According to the manufacturer\u2019s website, a 473ml bottle of BlueberryActive Concentrate sells for \u00a317.99 British pounds, or $21.85 in US dollars. Thirty blueberry capsules cost $13.35 in US dollars.", "answer": 0}, {"article": "A total of thirty 10-minute conversations were recorded.\nA relationship is obviously so much more than that.\u201d\n\nMembers of Williams\u2019s research team visited 15 couples in their home once a week for 10 weeks.\nIn analyzing the recordings, Williams identified 10 communication patterns that caregiving spouses used to connect with their partners and show affection.\nYet Williams hopes that the more supportive and positive communication patterns that many of the caregivers showed will help nurses coach spouses and family members affected by Alzheimer\u2019s.\nThey included sharing news about friends or relatives or plans for the day as a way to involve their spouse in day-to-day events; waiting patiently and keeping eye contact while spouses searched for words; and finding alternate ways to communicate \u2014 for example, singing songs together when attempts to engage the spouse in certain topics failed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed. In fairness, the use of the strategies revealed by this study really costs nothing, but there has to be some educational component to train caregiver spouses in their use, and such instruction would carry some cost. The story could have given us some idea of what might be entailed.", "answer": 0}, {"article": "But, she adds, epidemiological studies consistently show positive health effects from fish consumption on mortality, cardiovascular risk factors and, now, dementia.\nThe average level of DHA among all the participants was 3.6 percent of all fatty acids, and the top 25 percent of the population had values above 4.2 percent.\nThe finding that DHA alone reduces risk, the authors write, is consistent with earlier data showing high levels of DHA in healthy brain tissue and low levels in the brains of people with Alzheimer\u2019s disease.\nIn fact, fish intake accounted for less than half of the variability in DHA levels.\nThe study was financed in part by Martek, a concern that manufactures DHA, and one author received a grant from Pfizer, France.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not include any cost estimates for fish or\u00a0docosaheaenoic acid (DHA)\u00a0containing supplements.\u00a0 It also did not include an estimate for the amount of supplements that would be needed to result in the plasma levels of DHA seen to be associated with lower dementia risk.", "answer": 0}, {"article": "\"We have pioneered the development of a closed-loop artificial pancreas because we believe it will significantly impact the lives of individuals with both type 1 and type 2 diabetes, by providing exquisite control of blood sugar,\" Dr. Richard A. Insel, executive vice president for research at the Juvenile Diabetes Research Foundation (JDRF), said during a noon teleconference Saturday.\nWith the technology, patients maintained their blood sugar levels within the target range for 70 percent of the time, compared to 47 percent of the time among those not using the technology.\nThe promise of this emerging technology is to free diabetics from the need to constantly monitor their blood sugar levels by letting a computer program do the job -- constantly adjusting glucose and insulin levels as needed.\nThe device delivers two hormones that are deficient in type 1 diabetes -- insulin, which keeps blood sugar levels from going too high after a meal, and glucagon, a naturally occurring hormone that prevents blood sugar levels from dropping too low.\n\"We know that CGM success or failure is as dependent on the human experience as it is on the perfection of the technology,\" she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of the new approach or the currently available components, continuous glucose monitors and insulin pumps, are not described.\u00a0The two components are not cheap and many insurance companies aren\u2019t covering them except in special circumstances.", "answer": 0}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Researchers have only tested chondroitinase ABC (ChABC) on animals and it\u2019s understandable that costs would not be discussed at this point.\u00a0 ", "answer": 2}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "As we noted in our review of TIME Magazine\u2019s story as well: Although there may not yet be any accurate prediction of the cost of the particular therapy described for this single patient, it is generally well established and well documented that immunotherapies\u2013particularly those that involve modifying a patient\u2019s own immune cells\u2013are many times more expensive than standard treatments, sometimes running to annualized costs in the hundreds of thousands of dollars. \u00a0This story\u00a0says nothing about this.", "answer": 0}, {"article": "Messing says this misses the point of his study, which appears in the online July 30 issue of the journal Cancer.\n\"By not using PSA tests in the vast majority of men, you have to accept you are going to increase very serious metastatic disease threefold,\" says study leader Edward Messing, MD, chief of urology at the University of Rochester Medical Center.\nIt finds that in the three years before widespread PSA testing (1983-1985), men getting their first diagnosis of prostate cancer were three times more likely to learn they had very late-stage cancer than men diagnosed in the most recent three years for which data is available (2006-2008).\nJuly 30, 2012 -- If it weren't for routine PSA prostate cancer screening, an extra 17,000 Americans each year would learn that they had the worst form of the disease, a new study suggests.\nFor example, Kramer says, what if a man got a PSA test when his prostate cancer was in the very earliest stages of metastatic disease?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no cost information in the story, and this is a big gap seen in other stories that covered the topic \u2013 in TIME.com and HealthDay. Mentioning the cost of a PSA test and whether insurance typically covers it would have been great, as well as the costs of some of the subsequent tests and treatments.", "answer": 0}, {"article": "CHICAGO (Reuters) - Measuring certain proteins in spinal fluid can accurately diagnose Alzheimer\u2019s and predict which patients with memory problems will develop the fatal brain-wasting disease, Belgian researchers said on Monday.\nAnd they may also help identify early signs of the disease in healthy people, the team reported in the Archives of Neurology.\nWhen they looked to see how accurate these signatures were at spotting the disease, they found 90 percent of those with Alzheimer\u2019s had the disease pattern in their spinal fluid.\nBut biomarkers \u2014 proteins and imaging techniques \u2014 are helping to identify the disease much earlier.\nThey said measuring traces of beta amyloid and tau \u2014 two proteins associated with the telltale plaques and tangles that form in the brains of patients with Alzheimer\u2019s \u2014 accurately detected Alzheimer\u2019s in 90 percent of patients with the disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis story mentions neither estimates of the direct costs of such a test nor the indirect financial implications of testing before symptoms appear.", "answer": 0}, {"article": "When the appendix had burst, however, the open surgery racked up a considerably higher bill.\nBut it does suggest that laparoscopy could actually save thousands of dollars for some patients, when all costs \u2014 including physician fees, hospital fees and readmissions \u2014 are considered.\n\u201cSubstantial savings could be seen if open surgery is done in a laparoscopic fashion.\u201d\n\nBut he acknowledged that the study has major limitations.\nNEW YORK (Reuters Health) - Minimally invasive surgery for a burst appendix appears to be more successful and less costly in the long run than the traditional operation, a new study hints.\n\u201cYou really want to look at the total cost, because that\u2019s what society has to pay,\u201d said Dr. Dmitry Oleynikov, who heads the Center for Advanced Surgical Technology at Nebraska Medical Center in Omaha and led the new study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Nice job on this.\u00a0 The story states:\n\u201cFor uncomplicated cases of appendicitis, in which the appendix is still intact, the tabs for the two surgeries came out about the same, at just over $7,800. \u2026When the appendix had burst, however, the open surgery racked up a considerably higher bill. On average, it cost $17,594, compared to $12,125 for the laparoscopic surgery.\u201d\n\u00a0", "answer": 1}, {"article": "Researchers conducted a systematic review of existing peer-reviewed research evaluating infusion care for several conditions, including cystic fibrosis, antibiotics following orthopedic surgery and several cancers requiring infused chemotherapies.\nThe costs associated with home infusion were also consistently lower than services provided in a health care facility, with savings ranging between $1,928 and $2,974 per course of treatment.\n\"At CVS Health, we provide important home infusion services to patients through Coram, which is just one of the ways we are expanding our clinical delivery model and helping to move important health services to lower cost sites of care,\" added Alan Lotvin, MD, Executive Vice President, CVS Specialty.\nWhile many commercial health plans provide comprehensive coverage for home infusion services, Medicare has limited reimbursement for this type of care, and Congress is discussing how to implement a comprehensive home infusion benefit for Medicare beneficiaries.\n\"In fact, our patients report high satisfaction with our Coram home infusion services, citing convenience and comfort as key elements that improved their overall experience.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release includes information about costs. We would have liked a little more context. The release states: \u201cThe costs associated with home infusion were also consistently lower than services provided in a health care facility, with savings ranging between $1,928 and $2,974 per course of treatment.\u201d\nWe need to know what percentage of savings that is per course of treatment. If the whole course costs $100,000, then saving $1,928 is a pretty small percentage. If the whole course is $10,000, than a savings of $1,928 looks more substantial.", "answer": 1}, {"article": "GlaxoSmithKline is charging up to $98,000 for a six-month treatment course of Arzerra, a drug approved in late October for chronic lymphocytic leukemia, which strikes about 15,000 Americans a year.\n\u201cIt creates these huge ethical quandaries about trying a drug that has a modest benefit for the average patient at enormous expense.\u201d\n\nFolotyn is given by a rapid intravenous procedure once a week for six weeks out of every seven.\nIn the prospectus for that offering, the company said that one of the risks for investors was \u201cthe relative price of Folotyn as compared to alternate treatment options.\u201d It said there was a risk it might have to lower the price or offer discounts to successfully market Folotyn.\n\u201cIt\u2019s a two-edged sword that we have to live with and deal with,\u201d said Louis J. DeGennaro, chief scientific officer of the Leukemia and Lymphoma Society, which has received donations from Allos and other companies.\nMr. Schimmer\u2019s note was entitled \u201cFolotyn Prices High, Reiterate Outperform.\u201d He estimated annual sales of the drug in the United States reaching about $300 million by 2014.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story goes into some detail about the cost of Folotyn, which is extraordinarily high. The story also does a great job of comparing the cost of the drug to other expensive cancer drugs. Costs were the main focus of the story.", "answer": 1}, {"article": "Three years later, researchers continue to detect the presence of the cloned cells they infused into the patient, 61-year-old high school history teacher Gardiner Vinnedge of North Bend, Wash.\n\nFor six years, Vinnedge endured painful rounds of chemotherapy, only to have his melanoma return.\nThe immunotherapy allowed him to return to work three weeks after treatments began.\nAnother patient was declared in remission because his cancer ceased to spread and, after several months, disappeared altogether.\nThis type of \"adoptive immunotherapy\" could be effective against a wide range of cancers, Yee said.\nIn six of the 11 patients in the trial, the melanoma stopped progressing for 12 to 19 weeks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "An early experiment of immunotherapy against melanoma may be too early to allow for a cost estimate.", "answer": 2}, {"article": "Total energy intake was within the normal range.\n\"Our findings indicate that the overriding principle of a healthy diet is not the quantity of fat or carbohydrates, but the quality of the foods we eat,\" says PhD candidate Johnny Laupsa-Borge.\n\"These results indicate that most healthy people probably tolerate a high intake of saturated fat well, as long as the fat quality is good and total energy intake is not too high.\n\u2022 The Study is named (FATFUNC) and was performed by researchers at the KG Jebsen center for diabetes research, Department of Clinical Science at the University of Bergen.\n\"Future studies should examine which people or patients may need to limit their intake of saturated fat,\" assistant professor Simon Nitter Dankel points out, who led the study together with the director of the laboratory clinics, professor Gunnar Mellgren, at Haukeland university hospital in Bergen, Norway.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention costs but we won\u2019t fault it for this. We rate this Not Applicable since it would be very difficult to estimate the cost of shifting eating patterns that incorporate more foods laden with saturated fats.", "answer": 2}, {"article": "Test specificity was assessed in 212 presumed unexposed Spanish controls.\nThe TST is the most commonly used test to detect TB infection, with about 50 million tests worldwide each year, according to the World Health Organization.\nThe test, known as C-Tb, combines the \"field friendliness of the PPD-based tuberculin skin test with the high specificity of interferon gamma release assays, or IGRAs,\" said lead researcher Morten Ruhwald, MD, PhD, head of human immunology at Statens Serum Institut in Denmark, which developed the test.\nThe test is easy to administer but produces too many false positives to achieve the WHO's goal of reducing TB deaths by 95 percent and new cases by 90 percent by 2035, Dr. Ruhwald said.\nThe cost of a C-Tb test is to be determined; however, it is expected to be significantly less than an IGRA.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release provides a very good discussion of costs, stating, \u201cThere is also a dramatic price difference between the two diagnostic tests. According to Dr. Ruhwald, a TST costs about $2; an IGRA is 20 to 40 times more expensive depending on setting.\u201d This gives readers a clear idea of the fiscal advantage of using the new test.", "answer": 1}, {"article": "The researchers did not observe any side effects.\nEighteen women with high-grade precancerous cervical lesions participated in the phase 1 study.\nAlso, 18 people is a small number for examining the effects of a medication.\nHPV causes about 5% of cancers globally.\nBut there are a lot of people out there who still have HPV, and nothing protects against all 130 strains of the virus.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable; too early in development process to discuss costs.", "answer": 0}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed, which is unacceptable given that both drugs are already on the market. And the costs here are significant. Ten milliliters of Bavencio can cost more than $1,600. The cost of 180 one-milligram tablets of Inlyta can be more than $15,000. (What were the dosages used in this study? The story doesn\u2019t tell us.)", "answer": 0}, {"article": "The antidepressants can cause headache, nausea, dry mouth, dizziness and insomnia or sleepiness.\n\"I wouldn't encourage the mindset of putting women on these drugs thinking they're going to be on them for life,\" he said, adding that patients should try the drugs for a few months and then try to stop.\nIn the meantime, both Dr. Tice and Dr. Nelson said that for women who find their symptoms intolerable and want treatment, they would favor antidepressants over hormones.\nNow, other drugs have come into use for hot flashes, but not much is known about their effectiveness or long-term safety.\nThough hormones cause small increases in the risks for breast cancer and heart disease, a short course may still be the best choice for women with very severe symptoms, she said, though she added that women who have had breast cancer should definitely not take hormones.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of hormonal or non-hormonal treatments, which would be important to note if they are taken daily (or several times a day for some medications) for several months or years. ", "answer": 0}, {"article": "But study author Dong Wang, a graduate student with the departments of nutrition and epidemiology at Harvard T.H.\nAccording to study author Wang, trans fats have been almost eliminated from the food supply, so what is needed next is more taxation on sugary drinks and more regulations requiring salt to be reduced in food.\nTo get insight into the answer, they analyzed the results of seven health and nutrition surveys including almost 34,000 adults aged 20 and older between 1999 and 2012.\nAs a result, she said, it's crucial to look at a variety of studies and see if trends hold up.\nDr. Sonia Anand, a professor of medicine and epidemiology at McMaster University in Hamilton, Canada, praised the study, saying it's \"reasonable\" to link changes in diet to death rates in this way.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We are content to declare this Not Applicable, but it wouldn\u2019t have hurt to note the financial burden and potential financial savings accrued from fewer chronic diseases and deaths and bends in the rates of disease burden. A sentence or two would have strengthened the story.", "answer": 2}, {"article": "(Boston) -- To date, there are no methods that can quickly and accurately detect pathogens in blood to allow the diagnosis of systemic bloodstream infections that can lead to life-threatening sepsis.\nThe diagnostic assay is built on FcMBL, a genetically engineered pathogen-binding protein previously developed by Ingber and Michael Super, a Wyss Senior Staff Scientist who co-leads the Institute's pathogen-detecting effort.\nBiomarkers that report elevated inflammation are used clinically in the treatment of patients with sepsis; however, they fail to distinguish inflammation triggered by infectious pathogens from that induced by non-infectious causes, such as burns, traumas and surgeries.\nThe standard of care for detecting such blood-borne infections is blood culture, but this takes days to complete, only identifies pathogens in less than 30% of patients with fulminant infections, and it is not able to detect toxic fragments of dead pathogens that also drive the exaggerated inflammatory reactions leading to sepsis.\nWe are currently working to ready it for high-throughput use in clinical and point of care situations and to accelerate it even further,\" said Mark Cartwright, Ph.D., a Staff Scientist at the Wyss Institute and a lead-author on the study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Given that Wyss and its start-up company have experience with the pathogen detection technology the researchers developed, there likely is by now some sense of what the cost of the assay might be, or at least some idea of whether it would be more or less expensive than current laboratory tests. It\u2019s also important to note that such a test may be associated with additional downstream costs for testing or treatment.", "answer": 0}, {"article": "The new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nRyan Coller wins federal challenge for app to help children with complex care needs\n\nA team of researchers at the University of Wisconsin School of Medicine and Public Health and the College of Engineering have won a share of a $100,000 award to develop technology for families caring at home for children with complex medical needs...\nUW-Madison establishes state\u2019s first and only addiction hotline for providers\n\nIn what is believed to be a national first, the University of Wisconsin-Madison, in conjunction with UW Health, has established a new resource for Wisconsin primary-care physicians and other providers to help them successfully manage patients with...\nThe search committee for the Science and Medicine Graduate Research Scholars (SciMed) program director position enthusiastically announces four finalists who have been invited to give public presentations.\nView a new year's message from Dean Golden for 2019\n\nPlease take a moment to watch a special message from Robert N. Golden, MD, dean of the University of Wisconsin School of Medicine and Public Health, in which he reflects on 2018 and looks ahead to 2019.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The press release does not provide any indication of this drug combination cost. Since both drugs are on the market, some estimate should be possible.\nWe realize that university news releases may not be accustomed to being judged by a standard that calls for cost information. \u00a0But 70% of ~2,000 health care news stories we\u2019ve reviewed over the past 9 years were judged unsatisfactory on cost information. \u00a0So we\u2019re certainly not going to lower the bar for news releases, which could help to turn that trend around.", "answer": 0}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "For most Americans, access to a sauna would require membership in a health club or community center swimming pool, which is out of reach for many families. The story could have easily mentioned cost.", "answer": 0}, {"article": "Researchers recommend large-scale clinical trials to confirm that nighttime fasting results in favorable changes to biomarkers of glycemic control and breast cancer risk.\n\u201cThis is a simple dietary change that we believe most women can understand and adopt.\n\u201cIncreasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer,\u201d said Catherine Marinac, UC San Diego doctoral candidate and first author on the paper.\nThose who reported longer fast durations also indicated they consumed fewer calories per day, ate fewer calories after 10 p.m. and had fewer eating episodes.\nThe data shows that each three hour increase in nighttime fasting was associated with a 4 percent lower postprandial glucose level, regardless of how much women ate.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We will rule this criterion Not Applicable in this case because the intervention in question is fasting, which costs nothing.", "answer": 2}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nThe test has also shown promise in predicting which patients with mild memory loss are at high risk of developing the dreaded syndrome, which each year kills 66,000 Americans and inflicts incalculable heartache on the families of its victims.\n\"I do see great potential in this technology,\" said UCSF professor Dr. Lennart Mucke, director of the Gladstone Institute of Neurological Disease.\n\"\n\nThe Stanford professor and his team screened 120 such proteins that commonly circulate in the blood, and settled on 18 that showed the signature of Alzheimer's.\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Potential costs not addressed.\u00a0 However, this is not a commercially available test or even available in most research labs so costs are very difficult to predict.\u00a0 But a story like this also could have touched on the whole issue of the downstream costs associated with testing everyone who forgets someone\u2019s name or where they put their car keys \u2013 could be enormous \u2013 and the costs of providing what are now relatively ineffective current drug treaments.\u00a0\u00a0\u00a0 ", "answer": 2}, {"article": "Reiman wrote a commentary that accompanies the study in Nature.\nThe results are encouraging for pharmaceutical companies that have spent billions of dollars on efforts to come up with the first drug to treat the underlying cause of Alzheimer's.\n\"It was surprising, encouraging and thought-provoking to see such a striking reduction of existing plaques,\" Reiman says.\nBut last summer, Biogen began presenting its results with aducanumab at scientific meetings, including the Alzheimer's Association International Conference in July.\nAnd large studies showing that removing amyloid can preserve memory and thinking \"would go a long way toward validating the amyloid hypothesis,\" Sandrock says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention costs. However, the piece is clear that this is early-stage research that might not pan out, so we think it\u2019s acceptable that there\u2019s no cost discussion.", "answer": 2}, {"article": "TUESDAY, Aug. 2, 2011 (HealthDay News) -- There's still no cure for the common cold, but there may be a way to shorten its misery: A new study suggests that higher doses of zinc lozenges in certain formulations may cut the length of colds by more than 40 percent.\n\"When focusing on those studies which have used large daily doses of zinc, there is strong evidence that zinc lozenges shorten the duration of colds.\"\n\"In the evidence-based medicine framework, we are primarily interested in the question whether there is an effect, and how great, whereas the mechanism of the effect is a secondary issue,\" he said.\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\n\"I would tell my patients we still don't have a cure [for the common cold], and we don't know if zinc works.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention cost. But zinc lozenges are not expensive, costing perhaps $5 \u2013 $10 for a course of treatment.", "answer": 0}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s understandable that a story might not be able to discuss the costs of something that\u2019s 10 years away from availability. What is not so understandable, however, is why they did the story now. ", "answer": 2}, {"article": "The results were presented Thursday at the American College of Neuropsychopharmacology annual meeting in Hollywood, Fla.\nThe new drug -- called GLYX-13 -- is so far given in an intravenous form and was recently tested in patients who had not responded to other antidepressants.\nMany unknowns remain about the drug, including its long-term effects, whether some people won't respond to it and the effects of stopping its use.\nAn advantage is that the drug doesn't have the side effects of other drugs that target these same areas, such as hallucinations and schizophrenia-like symptoms, the researchers noted.\nGiven the results so far, he said, people won't need to take the drug every day, only once a week or less.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in this story, either for the new drug GLYX-13 or for existing drugs, such as Prozac, Paxil, Zoloft and Lexapro.", "answer": 0}, {"article": "Until more research is in, what should a woman with a personal history of breast cancer do?\nWith the MRI screen, \"we found cancer in just over 3 percent of women [with a personal history], which was double [that found in those with a genetic or family history],\" she said.\nCurrently, the American Cancer Society recommends annual breast MRI plus mammography for women at very high risk for breast cancer, such as those with a known genetic mutation known as BRCA or those with a very strong family history.\nStudying the effectiveness of MRI screening on all three groups of women, Dr. Wendy DeMartini, an assistant professor of radiology at the University of Washington Medical School, said MRI imaging found proportionally more cancers in women who had been treated for breast cancer than in the women considered at very high risk.\nMONDAY, Nov. 29, 2010 (HealthDay News) -- Women who have had breast cancer should consider annual screening with breast MRI in addition to an annual mammogram, new research indicates.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n\nAlthough the story acknowledges that women may need to pay for such imaging out of their own pockets, it does not provide any estimate of the cost\u2026 which may run more than $1000 per MRI scan. And since such testing is rarely a one-time event\u2026 women who choose to have MRI scans that are not covered by their health care insurance may spend thousands of dollars. \nOne estimate of the cost of MRI for women at an extremely high (50%) risk of developing breast cancer concluded that more than $50,000 was spent for each cancer found. \nAccording to the abstract of this study, cancers were found in 3 percent of the women with a history of breast cancer, which means that about 33 women were scanned for each cancer found, so the scanning cost would be somewhat more than $30,000 for each cancer found. And since conventional mammography was not part of this study, the researchers cannot claim that MRI found any tumors that would not have been found by conventional mammography, so there is no way to conclude from this data that there was any incremental advantage to adding MRI.\n", "answer": 0}, {"article": "Arena then hopes to file its request for market approval with the Food and Drug Administration by the end of 2009.\nThe experimental drug stimulates the 5-HT2C serotonin receptor, which is located in the hypothalamus, an area of the brain associated with regulation of food intake and metabolism.\nBut one of the two components of that drug made by Wyeth, fenfluramine, also hit a second target in the heart, which was linked to heart valve problems.\nThe company plans to announce results of the first Phase 3 clinical trial of the drug at the end of March, Chief Executive Jack Lief said.\nThat is the same receptor in the brain targeted by the weight loss drug Fen-phen, which was popular in the 1990s.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "If it\u2019s not too early to project that the drug may be submitted to the FDA for approval within a year, then it\u2019s not too early to get some estimate of cost or at least to give some context about the cost of other obesity drugs on the market.\u00a0 ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of the treatment.", "answer": 0}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that a whole-body DXA scan costs \u201c$45 to $350 or more\u201d and is generally not covered by insurance. While readers can do the math,\u00a0it would have been very useful for the story to point out what the costs of scanning at the intervals suggested (up to every 3 months) would amount to over time.", "answer": 1}, {"article": "That's when they learned cocoa compounds named epicatechin monomers enhanced beta cells' ability to secrete insulin.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\nBut rather than stocking up on the sugar-rich chocolate bars at the checkout line, researchers believe the starting point is to look for ways to take the compound out of cocoa, make more of it and then use it as a potential treatment for current diabetes patients.\n\"You probably have to eat a lot of cocoa, and you probably don't want it to have a lot of sugar in it,\" said study author Jeffery Tessem, assistant professor of nutrition, dietetics and food science at BYU.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This line of research is only at the most basic conceptual level so cost projections are unrealistic. However, there is an undercurrent in the message that suggests that this particular fraction of cocoa could be turned into a drug. When the release states that \u201cresearchers believe the starting point is to look for ways to take the compound out of cocoa, make more of it and then use it as a potential treatment for current diabetes patients\u201d it suggests big profits for a drug company, not the cocoa bean growers of South America.", "answer": 2}, {"article": "\"They did show a higher recurrence or progression rate with endometrial cancer than with AEH and that is consistent with other data,\" said Bakkum-Gamez, who added that the IUD method would not be appropriate for later-stage cancers, which tend to be more aggressive.\nNine of the women in the study successfully delivered babies.\nNo adverse effects from treatment were noted, according to the researchers, who declared no conflicts of interest.\nThe majority of these women have not yet had children, according to background information in the article.\nOf the patients with AEH, four later relapsed and required further treatment; of the women with early-stage cancer, two who had an initial complete response relapsed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention any costs of the IUD or other treatments.", "answer": 0}, {"article": "\"According to the data, PSA velocity does not add any value, but it may add more anxiety,\" Lu-Yao said.\nThe thought was that since high PSA levels are correlated with prostate cancer, rapidly rising levels of PSA, called \"PSA velocity,\" from one year to another would also be an indicator of prostate cancer.\nBut when they factored in other things that can influence risk, including a family history of the disease, being older, being black, PSA level and results of a digital rectal exam, there was virtually no association between PSA velocity and biopsy outcome.\nAnd many internal medicine and primary-care doctors, in part because of fears of litigation, do order biopsies based on fast-rising PSA levels, Brawley said.\nAs for PSA velocity, the ACS doesn't have a position on what PSA velocity warrants a biopsy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss the costs of PSA tests or provide estimates of the costs for following up an increase in PSA with a biopsy. These are significant cost issues, which warranted at least a line in the story. ", "answer": 0}]